Das Ergebnis unserer Forschung: Publikationen

Forschungsergebnisse

Veröffentlichungen der German Breast Group

Wir bei der GBG fühlen uns dazu verpflichtet, sämtliche Studien unabhängig von ihren Ergebnissen in qualitätsgesicherten, wissenschaftlichen Fachzeitschriften (Peer-Review-Verfahren) zu veröffentlichen. Dabei sind auch Widerlegungen von Annahmen, d.h. Annahmen, die sich in Studien nicht bestätigen ließen von öffentlichem Interesse.

Impact Factor von
0
für Forschungsbeiträge im Jahre 2022 erreicht.

Allein im Jahr 2022 sind von uns 67 Forschungsbeiträge mit einem Impact Factor von insgesamt 802 erschienen. Damit wird der akademisch-wissenschaftliche Schwerpunkt unseres Forschungsinstituts am besten erkennbar. Hier finden Sie die umfassende Sammlung unserer Erkenntnisse aus engagierter Arbeit und jahrelanger Brustkrebsforschung.

Für die Autorenschaft haben wir GBG intern Richtlinien entwickelt, die für maximale Transparenz sorgen, und Wertschätzung wissenschaftlicher Arbeit sorgen sollen (Guidelines for Authorship).

Publikationsübersicht

Dixon-Douglas J, Loibl S, Denkert C, Telli M, Loi S. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-13. doi: 10.1200/EDBK_351186. PMID: 35649211. (IF 1.000) pubmed.ncbi.nlm.nih.gov/35649211/ 

Furlanetto J, Marmé F, Loibl S. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon. Future Oncol. 2022 Sep;18(28):3199-3215. doi: 10.2217/fon-2022-0407. Epub 2022 Sep 7. PMID: 36069628. (IF 3.674) pubmed.ncbi.nlm.nih.gov/36069628/ 

Blohmer JU, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching PA, Schneeweiss A, Wimberger P, Seiler S, Huober J, Thill M, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, Loibl S; GBG and AGO-B. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1010-1018. doi: 10.1001/jamaoncol.2022.1059. PMID: 35588050; PMCID: PMC9121303. (IF 31.777) pubmed.ncbi.nlm.nih.gov/35588050/ 

van Mackelenbergh MT, Seither F, Möbus V, O'Shaughnessy J, Martin M, Joensuu H, Untch M, Nitz U, Steger GG, Miralles JJ, Barrios CH, Toi M, Bear HD, Muss H, Reimer T, Nekljudova V, Loibl S. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. Eur J Cancer. 2022 May;166:185-201. doi: 10.1016/j.ejca.2022.02.003. Epub 2022 Mar 16. PMID: 35305453. (IF 9.162) pubmed.ncbi.nlm.nih.gov/35305453/ 

Gerber B, Schneeweiss A, Möbus V, Golatta M, Tesch H, Krug D, Hanusch C, Denkert C, Lübbe K, Heil J, Huober J, Ataseven B, Klare P, Hahn M, Untch M, Kast K, Jackisch C, Thomalla J, Seither F, Blohmer JU, Rhiem K, Fasching PA, Nekljudova V, Loibl S, Kühn T. Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. Cancers (Basel). 2022 Jan 20;14(3):521. doi: 10.3390/cancers14030521. PMID: 35158789; PMCID: PMC8833390. (IF 6.575) pubmed.ncbi.nlm.nih.gov/35158789/ 

Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo JP, Metzger O, Dunbar M, Symmans WF, Rastogi P, Sohn JH, Young R, Wright GS, Harkness C, McIntyre K, Yardley D, Loibl S. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol. 2022 Apr;33(4):384-394. doi: 10.1016/j.annonc.2022.01.009. Epub 2022 Jan 31. PMID: 35093516. (IF 51.769) pubmed.ncbi.nlm.nih.gov/35093516/ 

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022 Mar;23(3):382-392. doi: 10.1016/S1470-2045(21)00758-0. Epub 2022 Feb 3. Erratum in: Lancet Oncol. 2022 Apr;23(4):e161. PMID: 35123662; PMCID: PMC8885431. (IF 41.316) pubmed.ncbi.nlm.nih.gov/35123662/ 

Gelber RD, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhart M; APHINITY Steering Committee and Investigators. Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. Eur J Cancer. 2022 May;166:219-228. doi: 10.1016/j.ejca.2022.01.031. Epub 2022 Mar 18. PMID: 35313167. (IF 9.162) pubmed.ncbi.nlm.nih.gov/35313167/ 

Denkert C, Loibl S. Response-based molecular subtyping-emergence of the third generation of breast cancer subtypes. Cancer Cell. 2022 Jun 13;40(6):592-594. doi: 10.1016/j.ccell.2022.05.012. PMID: 35700705. (IF 38.585) pubmed.ncbi.nlm.nih.gov/35700705/ 

Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clin Cancer Res. 2022 Jun 13;28(12):2587-2597. doi: 10.1158/1078-0432.CCR-21-3215. PMID: 35377948; PMCID: PMC9464605. (IF 12.531) pubmed.ncbi.nlm.nih.gov/35377948/ 

Lambertini M, Fielding S, Loibl S, Janni W, Clark E, Franzoi MA, Fumagalli D, Caballero C, Arecco L, Salomoni S, Ponde NF, Poggio F, Kim HJ, Villarreal-Garza C, Pagani O, Paluch-Shimon S, Ballestrero A, Del Mastro L, Piccart M, Bines J, Partridge AH, de Azambuja E. Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. J Natl Cancer Inst. 2022 Aug 8;114(8):1117-1126. doi: 10.1093/jnci/djac096. PMID: 35512402; PMCID: PMC9360461. (IF 11.816) pubmed.ncbi.nlm.nih.gov/35512402/ 

Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, O'Shaughnessy J, Cortés J, Diéras V, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo M, Itri LM, Kalinsky K. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2022 Aug 29;8(1):98. doi: 10.1038/s41523-022-00467-1. PMID: 36038616; PMCID: PMC9424318. (IF 7.519) pubmed.ncbi.nlm.nih.gov/36038616/ 

Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck N, Bondarenko I, Masuda N, Colleoni M, DeMichele A, Loi S, Iwata H, O'Leary B, André F, Loibl S, Bananis E, Liu Y, Huang X, Kim S, Lechuga Frean MJ, Turner NC. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clin Cancer Res. 2022 Aug 15;28(16):3433-3442. doi: 10.1158/1078-0432.CCR-22-0305. PMID: 35552673. (IF 12.531) pubmed.ncbi.nlm.nih.gov/35552673/ 

Amant F, Nekljudova V, Maggen C, Seither F, Neven P, Cardonick EH, Schmatloch S, Van Calsteren K, Cordes T, de Haan J, Lok CAR, Flock F, Boere IA, Gziri MM, Solbach C, Lefrère H, Schneeweiss A, Witzel I, Seiler S, Loibl S. Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls. Eur J Cancer. 2022 Jul;170:54-63. doi: 10.1016/j.ejca.2022.04.014. Epub 2022 May 17. PMID: 35594612. (IF 9.162) pubmed.ncbi.nlm.nih.gov/35594612/ 

Cui W, Phillips KA, Francis PA, Anderson RA, Partridge AH, Loi S, Loibl S, Keogh L. Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials. Breast. 2022 Aug;64:56-62. doi: 10.1016/j.breast.2022.05.002. Epub 2022 May 16. PMID: 35597179; PMCID: PMC9127191. (IF 4.254) pubmed.ncbi.nlm.nih.gov/35597179/ 

Laakmann E, Witzel I, Neunhöffer T, Park-Simon TW, Weide R, Riecke K, Polasik A, Schmidt M, Puppe J, Mundhenke C, Lübbe K, Hesse T, Thill M, Zahm DM, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry. ESMO Open. 2022 Jun;7(3):100495. doi: 10.1016/j.esmoop.2022.100495. Epub 2022 May 30. PMID: 35653983; PMCID: PMC9271494. (IF 6,883) pubmed.ncbi.nlm.nih.gov/35653983/ 

Carey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, Diamond JR, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, O'Shaughnessy J, Loibl S, Gianni L, Piccart M, Zhu Y, Delaney R, Phan S, Cortés J. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. NPJ Breast Cancer. 2022 Jun 9;8(1):72. doi: 10.1038/s41523-022-00439-5. PMID: 35680967; PMCID: PMC9184615. (IF 7.519) pubmed.ncbi.nlm.nih.gov/35680967/ 

Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. PMID: 35857659. (IF 91.245) pubmed.ncbi.nlm.nih.gov/35857659/ 

Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, Furlanetto J, Zahm DM, Hanusch C, Thomalla J, Jackisch C, Staib P, Link T, Rhiem K, Solbach C, Fasching PA, Nekljudova V, Denkert C, Untch M; GBG and AGO-B. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022 Nov;33(11):1149-1158. doi: 10.1016/j.annonc.2022.07.1940. Epub 2022 Aug 9. PMID: 35961599. (IF 51.769) pubmed.ncbi.nlm.nih.gov/35961599/ 

Zhu Z, Turner NC, Loi S, André F, Martin M, Diéras V, Gelmon KA, Harbeck N, Zhang C, Cao JQ, Yan Z, Lu DR, Wei P, VanArsdale TL, Rejto PA, Huang X, Rugo HS, Loibl S, Cristofanilli M, Finn RS, Liu Y. Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib. NPJ Precis Oncol. 2022 Aug 16;6(1):56. doi: 10.1038/s41698-022-00297-1. PMID: 35974168; PMCID: PMC9381541. (IF 10.092) pubmed.ncbi.nlm.nih.gov/35974168/ 

Hartmann S, Kühn T, Hauptmann M, Stickeler E, Thill M, Lux MP, Fröhlich S, Ruf F, Loibl S, Blohmer JU, Kolberg HC, Thiemann E, Weigel M, Solbach C, Kaltenecker G, Paluchowski P, Schrauder MG, Paepke S, Watermann D, Hahn M, Hufnagel M, Lefarth J, Untch M, Banys-Paluchowski M; Die AXSANA-Studiengruppe. Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA study. Geburtshilfe Frauenheilkd. 2022 Sep 13;82(9):932-940. doi: 10.1055/a-1889-7883. PMID: 36110892; PMCID: PMC9470287. (IF 2.915) pubmed.ncbi.nlm.nih.gov/36110892/ 

Loibl S, Huang CS, Mano MS, Mamounas EP, Geyer CE Jr, Untch M, Thery JC, Schwaner I, Limentani S, Loman N, Lübbe K, Chang JC, Hatschek T, Tesarowski D, Song C, Lysbet de Haas S, Boulet T, Lambertini C, Wolmark N. Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. NPJ Breast Cancer. 2022 Sep 19;8(1):106. doi: 10.1038/s41523-022-00477-z. PMID: 36117201; PMCID: PMC9482917. (IF 7.741) pubmed.ncbi.nlm.nih.gov/36117201/ 

Galactionova K, Loibl S, Salari P, Marmé F, Martin M, Untch M, Bonnefoi HR, Kim SB, Bear HD, McCarthy N, Gelmon KA, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Gnant M, Makris A, Burchardi N, Schwenkglenks M. Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial. Front Oncol. 2022 Sep 5;12:886831. doi: 10.3389/fonc.2022.886831. PMID: 36132153; PMCID: PMC9484462. (IF 5.738) pubmed.ncbi.nlm.nih.gov/36132153/ 

Schmidt M, Lübbe K, Decker T, Thill M, Bauer L, Müller V, Link T, Furlanetto J, Reinisch M, Mundhenke C, Hoffmann O, Zahn MO, Müller L, Denkert C, van Mackelenbergh M, Fasching PA, Burchardi N, Nekljudova V, Loibl S. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE). ESMO Open. 2022 Dec;7(6):100601. doi: 10.1016/j.esmoop.2022.100601. Epub 2022 Nov 7. PMID: 36356410. (IF 6.883) pubmed.ncbi.nlm.nih.gov/36356410/ 

Leichsenring J, Vladimirova V, Solbach C, Karn T, Ataseven B, Sinn BV, Barinoff J, Müller V, Blohmer JU, Schem C, Engels K, Marmé F, Fisseler-Eckhoff A, Fasching PA, Stickeler E, van Mackelenbergh M, Denkert C, Stenzinger A, Loibl S, Gröschel S. EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy. BMC Cancer. 2022 Oct 5;22(1):1040. doi: 10.1186/s12885-022-10109-1. PMID: 36195836; PMCID: PMC9533588. (IF 4.43) pubmed.ncbi.nlm.nih.gov/36195836/ 

Reinisch M, Untch M, Mahlberg R, Reimer T, Hitschold T, Marmé F, Aydogdu M, Schmatloch S, Lück HJ, Schmidt M, Ladda E, Sinn BV, Klare P, Janni W, Jackisch C, Denkert C, Seiler S, Göhler T, Michel L, Burchardi N, Stickeler E, Rey J, Klutinus N, Möbus V, Loibl S. Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study. Breast. 2022 Dec;66:110-117. doi: 10.1016/j.breast.2022.10.002. Epub 2022 Oct 5. PMID: 36223695; PMCID: PMC9563210. (IF 4.254) pubmed.ncbi.nlm.nih.gov/36223695/ 

Swain SM, Tan AR, Gianni L, Kuemmel S, Dang CT, Schneeweiss A, O'Shaughnessy J, Liu H, Aguila C, Heeson S, Macharia H, Yang K, Restuccia E, Loibl S. Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. Eur J Cancer. 2023 Jan;178:70-81. doi: 10.1016/j.ejca.2022.09.024. Epub 2022 Oct 7. PMID: 36410207. (IF 9.433) pubmed.ncbi.nlm.nih.gov/36410207/ 

Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. PMID: 36228963. (IF 51.769) pubmed.ncbi.nlm.nih.gov/36228963/ 

Dixon-Suen SC, Lewis SJ, Martin RM, English DR, Boyle T, Giles GG, Michailidou K, Bolla MK, Wang Q, Dennis J, Lush M, Investigators A, Ahearn TU, Ambrosone CB, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Augustinsson A, Auvinen P, Beane Freeman LE, Becher H, Beckmann MW, Behrens S, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Brenner H, Brüning T, Buys SS, Camp NJ, Campa D, Canzian F, Castelao JE, Cessna MH, Chang-Claude J, Chanock SJ, Clarke CL, Conroy DM, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Fletcher O, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Goldberg MS, Guénel P, Gündert M, Hahnen E, Haiman CA, Häberle L, Håkansson N, Hall P, Hamann U, Hart SN, Harvie M, Hillemanns P, Hollestelle A, Hooning MJ, Hoppe R, Hopper J, Howell A, Hunter DJ, Jakubowska A, Janni W, John EM, Jung A, Kaaks R, Keeman R, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Kubelka-Sabit K, Kurian AW, Lacey JV, Lambrechts D, Le Marchand L, Lindblom A, Loibl S, Lubiński J, Mannermaa A, Manoochehri M, Margolin S, Martinez ME, Mavroudis D, Menon U, Mulligan AM, Murphy RA, Collaborators N, Nevanlinna H, Nevelsteen I, Newman WG, Offit K, Olshan AF, Olsson H, Orr N, Patel A, Peto J, Plaseska-Karanfilska D, Presneau N, Rack B, Radice P, Rees-Punia E, Rennert G, Rennert HS, Romero A, Saloustros E, Sandler DP, Schmidt MK, Schmutzler RK, Schwentner L, Scott C, Shah M, Shu XO, Simard J, Southey MC, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Tollenaar RAEM, Troester MA, Truong T, Untch M, Vachon CM, Joseph V, Wappenschmidt B, Weinberg CR, Wolk A, Yannoukakos D, Zheng W, Ziogas A, Dunning AM, Pharoah PDP, Easton DF, Milne RL, Lynch BM; Breast Cancer Association Consortium. Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study. Br J Sports Med. 2022 Oct;56(20):1157-1170. doi: 10.1136/bjsports-2021-105132. Epub 2022 Sep 6. PMID: 36328784. (IF 18.473) pubmed.ncbi.nlm.nih.gov/36328784/ 

Loibl S, Loirat D, Tolaney SM, Punie K, Oliveira M, Rugo HS, Bardia A, Hurvitz SA, Brufsky AM, Kalinsky K, Cortés J, O'Shaughnessy JA, Dieras V, Carey LA, Gianni L, Gharaibeh M, Preger L, Phan S, Chang L, Shi L, Piccart MJ. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. Eur J Cancer. 2023 Jan;178:23-33. doi: 10.1016/j.ejca.2022.10.003. Epub 2022 Oct 18. PMID: 36379186. (IF 9.162) pubmed.ncbi.nlm.nih.gov/36379186/ 

Prat A, Bardia A, Curigliano G, Hammond MEH, Loibl S, Tolaney SM, Viale G. An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low). JAMA Oncol. 2022 Sep 15. doi: 10.1001/jamaoncol.2022.4175. Epub ahead of print. PMID: 36107417. (IF 31.777) pubmed.ncbi.nlm.nih.gov/36107417/ 

Conforti F, Pala L, Bagnardi V, De Pas T, Colleoni M, Buyse M, Hortobagyi G, Gianni L, Winer E, Loibl S, Cortes J, Piccart M, Wolff AC, Viale G, Gelber RD. Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations. JAMA Oncol. 2022 Nov 1;8(11):1668-1675. doi: 10.1001/jamaoncol.2022.3755. PMID: 36201176. (IF 31.777) pubmed.ncbi.nlm.nih.gov/36201176/ 

Reimer T, Stachs A, Veselinovic K, Polata S, Müller T, Kühn T, Heil J, Ataseven B, Reitsamer R, Hildebrandt G, Knauer M, Golatta M, Stefek A, Zahm DM, Thill M, Nekljudova V, Krug D, Loibl S, Gerber B; INSEMA investigators. Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer. EClinicalMedicine. 2022 Nov 25;55:101756. doi: 10.1016/j.eclinm.2022.101756. PMID: 36457648; PMCID: PMC9706517. (IF 11.492) pubmed.ncbi.nlm.nih.gov/36457648/ 

Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz SA, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. JAMA Oncol. 2022 Dec 1:e225610. doi: 10.1001/jamaoncol.2022.5610. Epub ahead of print. PMID: 36454580; PMCID: PMC9716438. (IF 31.777) pubmed.ncbi.nlm.nih.gov/36454580/ 

Loibl, S., Seiler, S. Schwangerschaft nach Krebs. Forum. 2022 Dec 29. doi.org/10.1007/s12312-022-01163-8 (IF n.a.) 

 https://link.springer.com/article/10.1007/s12312-022-01163-8  

Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022 Mar;33(3):321-329. doi: 10.1016/j.annonc.2021.12.005. Epub 2021 Dec 23. Erratum in: Ann Oncol. 2022 Dec 21;: PMID: 34954044. (IF 51.769) pubmed.ncbi.nlm.nih.gov/34954044/ 

Maschmeyer G, Loibl S, Fehm T, Hilgendorf I, Dittrich R. Management onkologischer Erkrankungen in der Schwangerschaft. Forum (2022). doi.org/10.1007/s12312-022-01134-z (IF n.a.) https://link.springer.com/article/10.1007/s12312-022-01134-z 

Francis PA, Fleming GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B, Burstein HJ, Davidson NE, Geyer CE Jr, Walley BA, Ingle JN, Coleman RE, Müller B, Le Du F, Loibl S, Winer EP, Ruepp B, Loi S, Colleoni M, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation). Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2022 Dec 9:JCO2201065. doi: 10.1200/JCO.22.01065. Epub ahead of print. PMID: 36493334. (IF 50.717) pubmed.ncbi.nlm.nih.gov/29863451/ 

  • Curigliano G, Mueller V, Borges V, et al. Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis. Ann Oncol. 2021; doi: 10.1016/j.annonc.2021.12.005. 
    Loibl S, Furlanetto J. Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer. Breast. 2021; doi: 10.1016/j.breast.2021.12.008. 
     
  • Wege AK, Rom-Jurek EM, Jank P, et al. mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease. Int J Cancer. 2021; doi: 10.1002/ijc.33911. 
     
  • Schneeweiss A, Michel LL, Möbus V, et al. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. Eur J Cancer. 2022;160:100-111 (Epub 2021). 
     
  • Metzger-Filho O, Collier K, Asad S, et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. NPJ Breast Cancer. 2021;7:142. 
     
  • Jurmeister P, Weber K, Villegas S, et al. DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. Clin Epigenetics. 2021;13:184. 
     
  • Llop-Guevara A, Loibl S, Villacampa G, et al. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Ann Oncol. 2021;32:1590-1596. 
     
  • Bardia A, Hurvitz SA, Rugo HS, et al. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. Future Oncol. 2021;17:3911-3924. 
     
  • Möbus V, Lück HJ, Ladda E, et al. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). Eur J Cancer. 2021;156:138-148. 
     
  • Schrodi S, Braun M, Andrulat A, et al. Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. Ann Oncol. 2021;32:1410-1424. 
     
  • Stürken C, Möbus V, Milde-Langosch K, et al. TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer. BMC Cancer. 2021;21:920. 
    Jerusalem G, Farah S, Courtois A, et al. Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. Ann Oncol. 2021;32:1256-1266. 
     
  • Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 2021;22:1139-1150. 
     
  • Lefrère H, Floris G, Schmidt MK, et al. Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. Eur J Cancer. 2021;155:13-24. 
     
  • Coombes RC, Tovey H, Kilburn L, et al. Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. JAMA Oncol. 2021 Jul 15:e212193. 
     
  • Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22:1151-1161. 
     
  • Marmé F, Solbach C, Michel L, et al. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer. 2021 Aug;153:203-212. 
     
  • Aftimos P, Oliveira M, Irrthum A, et al. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. Cancer Discov. 2021;11:2796-2811. 
     
  • Furlanetto J, Marmé F, Seiler S, et al. Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials. Eur J Cancer. 2021;152:193-203. 
     
  • Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021;384:2394-2405. 
    Cui W, Francis PA, Loi S, Hickey M, Stern C, Na L, Partridge AH, Loibl S, 
     
  • Anderson RA, Hutt KJ, Keogh LA, Phillips KA. Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation. J Natl Cancer Inst. 2021 28;113:1770-8. 
     
  • Rugo HS, Cristofanilli M, Loibl S, et al. Prognostic Factors for Overall Survival in Patients With Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. Oncologist. 2021;26:e1339-e1346. 
     
  • Terrisse S, Derosa L, Lebba V, et al. Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death Differ. 2021;28:2778-2796. 
     
  • Mamounas EP, Untch M, Mano MS, et al. Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE. Ann Oncol. 2021;32:1005-1014. 
     
  • Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384:1529-1541. 
     
  • Loibl S, Marmé F, Martin M, et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol. 2021; 39:1518-1530. 
     
  • Ciruelos EM, Rugo HS, Mayer IA, et al. Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. J Clin Oncol. 2021;39:2005-2015. 
     
  • Villegas SL, Nekljudova V, Pfarr N, et al. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. Eur J Cancer. 2021;148:159-170. 
     
  • Riecke K, Müller V, Weide R, et al. Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic Scores. Cancers (Basel). 2021;13:844. 
     
  • Filho OM, Stover DG, Asad S, et al. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7:603-608. 
     
  • Sinn BV, Loibl S, Hanusch CA, et al. Immune-related gene expression predicts response to neoadjuvant chemotherapy but not additional benefit from PD-L1 inhibition in women with early triple-negative breast cancer. Clin Cancer Res. 2021;27:2584-2591. 
     
  • Edlund K, Madjar K, Lebrecht A, et al. Gene expression-based prediction of neoadjuvant chemotherapy response in early breast cancer: results of the prospective multicenter EXPRESSION trial. Clin Cancer Res. 2021;27:2148-2158. 
     
  • Reinisch M, Seiler S, Hauzenberger T, et al. Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7:565-572. 
     
  • Denkert C, Untch M, Benz S, et al. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy. Ann Oncol. 2021;32:500-511. 
     
  • Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;22:212-222. 
     
  • El Bairi K, Haynes HR, Blackley E, et al. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021;7:150. 
     
  • Loi S, Michiels S, Adams S, et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol. 2021;32:1236-1244. 
     
  • Polley MC, Dickler MN, Sinnwell J, et al. A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. Breast Cancer Res Treat. 2021;189:15-23. 
     
  • Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750-1769. 
     
  • Dubsky P, Pinker K, Cardoso F, et al. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. Lancet Oncol. 2021;22:e18-e28.

SABCS: San Antonio Breast Cancer Symposium, December 7-10, 2021

  • Gerber B, Stachs A, Veselinovic K et al. Patient-reported outcomes (PROs) for the intergroup sentinel mamma study (INSEMA, GBG75, ABCSG43): Persistent impact of axillary surgery on arm and breast symptoms in early breast cancer. SABCS 2021; abstract GS4-03, oral presentation.
    Denkert C, Marmé F, Martin M, et al. Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib. SABCS 2021; abstract PD2-04, poster discussion.
     
  • Wege AK, Vladimirova V, Solbach C, et al. Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer. SABCS 2021; abstract PD9-07, poster discussion.
     
  • Marmé F, Schmidt M, Furlanetto J, et al. Phase III postneoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA. SABCS 2021; abstract OT1-02-01, TIP.
     
  • Galas K, Gleitsmann M, Rey J, et al. Immunological markers in patients with breast cancer occurring during pregnancy - Results from GBG BCP study. SABCS 2021; abstract P4-04-14, poster.
     
  • Loibl S, Hauke J, Gelmon K, et al. Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study. SABCS 2021; abstract P5-13-36, poster.
     
  • Regan MM, Walley BA, Fleming GF, et.al. Randomized comparison of adjuvant aromatase inhibitor exemestane + ovarian function suppression (OFS) vs tamoxifen + OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer: update of the TEXT and SOFT trials. SABCS 2021; abstract GS2-05, oral presentation.
     
  • Gnant M, Dueck AC, Frantal S, et al. Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial. SABCS 2021; abstract PD2-09, poster discussion.
     
  • Naughton MJ, Zahrieh D, Gnant M, et al. Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05). SABCS 2021; abstract P4-10-01, poster.
     
  • Ganz PA, Bandos H, Spanic T, et al. Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer. SABCS 2021; abstract GS4-09, oral presentation.
     
  • Geyer, Jr CE, Untch M, Prat, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05). SABCS 2021; abstract OT1-02-03, TIP.
     
  • Loibl S, Tolaney SM, Punie K, et al. Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple‑negative breast cancer (mTNBC). SABCS 2021; abstract P5-16-01, poster.

ESMO: European Society for Medical Oncology, September 16-21, 2021, Virtual Meeting

  • Loibl S, Schmidt M, Lübbe K, et al. A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE). Ann Oncol. 2021; 32 (suppl_5): S1292-S1293, LBA19 mini oral presentation.
     
  • García-Saenz J, Marmé F, Rugo H, et al. Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib. Ann Oncol. 2021; 32 (suppl_5): S407-S446, 122MO mini oral presentation.
     
  • Galactionova K, Loibl S, Salari P, et al. Health economic properties of Palbociclib in breast cancer patients with high risk of relapse following neoadjuvant therapy – results from the Penelope-B trial. Ann Oncol. 2021; 32 (suppl_5): S407-S446, 132P ePoster.
     
  • Marmé F, Hanusch C, Furlanetto J, et al. Phase III postneoadjuvant study evaluating Sacituzumab Govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA. Ann Oncol. 2021; 32 (suppl_5): S407-S446, 199TiP ePoster.
     
  • Loibl S, Sikov W, Huober J, et al. Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized Phase 3 trial. Ann Oncol. 2021; 32 (suppl_5): S408, 119O oral presentation.
     
  • Loibl S, Loirat D, Tolaney SM, et al. Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2021; 32 (suppl_5): S457-S515, 257P ePoster.
     
  • Franzoi MA, Martel S, Agbor-Tarh D, et al. Impact of body mass (BMI) and weight change after adjuvant treatment in patients (pts) with HER2-positive early breast cancer. Ann Oncol. 2021; 32 (suppl_5): S415-S416, 131P ePoster.
     

Senologiekongress 2021, June 17-19, 2021, Virtual Meeting

  • Laakmann E, Witzel I, Neunhöffer T et al. Characteristics of patients with brain metastases from HER2-positive breast cancer. oral presentation.
     
  • Untch M, Geyer Jr CE, Prat A, et al. Trastuzumab-Deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer (BC) after neoadjuvant therapy (NAT): a randomized, phase 3 trial (DESTINY-Breast05). TIP

ASCO: American Society of Clinical Oncology, Annual Meeting June 4-8, 2021, Virtual Meeting

  • Loibl S, Schneeweiss A, Huober J, et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol. 2021; 39.15_suppl.506, oral presenation.
     
  • Denkert C, Marmé F, Matrtin M, et al. Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease. J Clin Oncol. 2021; 39.15_suppl.519, poster discussion.
     
  • Marmé F, Martin M, Untch M, et al. Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B. J Clin Oncol. 2021; 39.15_suppl.518, poster discussion.
     
  • Amant F, Nekljudova V, Maggen C, et al. Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls. J Clin Oncol. 2021; 39.15_suppl.515, poster discussion.
     
  • Marmé F, Stickeler E, Furlanetto J, et al. Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. J Clin Oncol. 2021; 39.15_suppl.TPS602, TIP.
     
  • De Azambuja E, Eiger D, Procter MJ, et al. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial. J Clin Oncol. 2021; 39.15_suppl.510, poster discussion.
     
  • Tutt A, Garber JE, Kaufman B et al. OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. J Clin Oncol. 2021; 39.15_suppl. LBA1, oral presentation.
     
  • Kalinsky K, Oliviera M, Traina TA, et al. Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). J Clin Oncol. 2021; 39.15_suppl.1011, oral presentation.
     
  • Carey LA, Loirat D, Punie K, et al. Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). J Clin Oncol. 2021; 39.15_suppl.1080, ePoster.
     
  • Curligliano G, Mueller V, Borges VF, et al. Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). J Clin Oncol. 2021; 39.15_suppl. 1043, ePoster.
     

ESMO-Breast Cancer May 5-8, 2021, Virtual Meeting

  • Llop-Guevara A, Vladimirova V, Schneeweiss A et al. Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Ann Oncol. 2021; 32 (suppl_2): S21-S36, O2 oral presentation.
     
  • Laakmann E, Witzel I, Neunhöffe T et al. Characteristics of patients with brain metastases from HER2-positive breast cancer. Ann Oncol. 2021; 32 (suppl_2): S60-S78, 95MO mini oral presentation.
     
  • Furlanetto J, Denkert C, Untch M, et al. Impact of body mass index (BMI) on prognostic and predictive value of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): a pooled analysis of six neoadjuvant trials. Ann Oncol. 2021; 32 (suppl_2): S27-S28, 17P ePoster.
     
  • Vladimirova V, Schneeweiss A, Jackisch C, et al. BACH1 and HIF1α predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC). Ann Oncol. 2021; 32 (suppl_2): S29, 21P ePoster.
     
  • Leichsenring J, Vladimirova V, Solbach C, et al. EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy. Ann Oncol. 2021; 32 (suppl_2): S32, 28P ePoster.
     
  • Labidi-Galy I, Schneeweiss A, Sinn HP, et al. Baseline menopausal status, Ki-67 and stromal tumor-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): exploratory analysis in GeparSixto. Ann Oncol. 2021; 32 (suppl_2): S49-S50, 66P ePoster.
  • Furlanetto J, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Lübbe K, Untch M et al. Germline BRCA1/2 mutations and severe hematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer. 2021; 145:44-52.
  • Reimer T, Glass A, Botteri E, Loibl S, D Gentilini O. Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial. Cancers (Basel). 2020;12:3698.
  • Kolberg HC, Kühn T, Krajewska M, Bauerfeind I, Fehm TN, Fleige B, et al. Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases - a transSENTINA Analysis. Geburtshilfe Frauenheilkd. 2020;80:1229-1236.
     
  • André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1. Ann Oncol. 2020; doi: 10.1016/j.annonc.2020.11.011.
     
  • Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer JU, Zahm DM, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching PA, Untch M, Loibl S, Weber K, Seliger B. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J Immunother Cancer. 2020; 8:e001261.
     
  • Rüger AM, Schneeweiss A, Seiler S, Tesch H, van Mackelenbergh M, Marmé F, et al. Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial. J Am Heart Assoc. 2020;9:e018143.
     
  • Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, et al. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clin Breast Cancer. 2020; doi: 10.1016/j.clbc.2020.09.014.
     
  • Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol. 2020; doi: 10.1016/j.annonc.2020.10.471.
     
  • Guerini-Rocco E, Gray KP, Fumagalli C, Reforgiato MR, Leone I, Rafaniello Raviele P, et al. Genomic aberrations and late recurrence in postmenopausal women with hormone receptor-positive early breast cancer: Results from the SOLE Trial. Clin Cancer Res. 2020; doi: 10.1158/1078-0432.CCR-20-0126.
     
  • Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon TW, et al. Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. Cancers (Basel). 2020; 12:2787.
     
  • O'Leary B, Cutts RJ, Huang X, Hrebien S, Liu Y, André F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M, Bartlett CH, Turner NC. Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. J Natl Cancer Inst. 2020; djaa087.
     
  • Jank P, Gehlhaar C, Lederer B, Fontanella C, Schneeweiss A, Karn T, et al. MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial. PLoS One. 2020;15:e0238021.
     
  • Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, et al. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol. 2020;38:2610-2619.
     
  • Karn T, Denkert C, Weber KE, Holtrich U, Hanusch C, Sinn BV, et al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol. 2020;31:1216-1222.
     
  • Hildebrandt G, Stachs A, Gerber B, Potenberg J, Krug D, Wolter K, et al. Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial. Int J Radiat Oncol Biol Phys. 2020;107:683-693.
     
  • Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, et al. Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer. Ann Oncol. 2020;31:1001-1010.
     
  • Conte P, Schneeweiss A, Loibl S, Mamounas EP, von Minckwitz G, Mano MS, et al. Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. Cancer. 2020;126:3132-3139. 
     
  • Werutsky G, Untch M, Hanusch C, Fasching PA, Blohmer JU, Seiler S, et al. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. Eur J Cancer. 2020;130:92-101.
     
  • Pohl-Rescigno E, Hauke J, Loibl S, Möbus V, Denkert C, Fasching PA, et al. Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial. JAMA Oncol. 2020;6:744-748. 
     
  • Karn T, Meissner T, Weber K, Solbach C, Denkert C, Engels K, et al. A small hypoxia signature predicted pCR response to bevacizumab in the neoadjuvant GeparQuinto breast cancer trial. Clin Cancer Res. 2020; 26:1896-1904. 
     
  • Guo S, Loibl S, Minckwitz GV, Darb-Esfahani S, Lederer B, Denkert C. PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy. Cancer Res Treat. 2020;52:689-696. 
     
  • Sonnenblick A, Salmon-Divon M, Salgado R, Dvash E, Pondé N, Zahavi T, et al. Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. Int J Cancer. 2020;147:266-276. 
     
  • Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382:597-609. 
     
  • Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, et al. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer. 2020;6:17.
     
  • Furlanetto J, Loibl S. Optimal Systemic Treatment for Early Triple-Negative Breast Cancer. Breast Care (Basel). 2020;15:217-226.
     
  • Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las Heras B, et al. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. Br J Cancer. 2020; 123:694-697.
     
  • de Azambuja E, Trapani D, Loibl S, Delaloge S, Senkus E, Criscitiello C, et al. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. ESMO Open. 2020;5(Suppl 3):e000793.
     
  • Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, et al. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. NPJ Breast Cancer. 2020;6:15. Published 2020; 6:15.
     
  • Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, et al. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2020;6:16.
     
  • Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, et al. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol. 2020;250:667-684.

SABCS: San Antonio Breast Cancer Symposium, December 8-11, 2020, Virtual Meeting

  • Loibl S, Marmé F, Martin M, et al. Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B. SABCS 2020, Abstract GS1-02.
     
  • Sestak I, Cuzick J, Bonanni B, et al. 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ. SABCS 2020, Abstract GS2-02.
    Krop I, Mittempergher L, Paulson J, et al. BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: a biomarker analysis of the APHINITY trial. SABCS 2020, Abstract PD3-01.
     
  • Ciruelos EM, Loibl S, Mayer IA, et al. Clinical Outcomes of Alpelisib Plus Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer With PIK3CA Alterations Detected in Plasma ctDNA by Next-Generation Sequencing: Biomarker Analysis From the SOLAR-1 Study. SABCS 2020, Abstract PD2-06.
     
  • Mayer EL, Fesl C, Dueck A et al. Treatment exposure and discontinuation in the PALLAS trial: PALbociclib CoLlaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for HR+/HER2- early breast cancer. SABCS 2020, Abstract PD2-03.
     
  • Franzoi MA, Procter M, Emond O, et al. Timelines to initiate an adjuvant phase III trial across the globe: a sub-analysis of the APHINITY trial. SABCS 2020, Abstract PS7-21.
     
  • Gelber RD, Wang XV, Cole BF, et al. 6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: a STEPP analysis of the APHINITY (BIG 4-11) trial. SABCS 2020, Abstract PS10-01.
     
  • Núria N, Luen SJ, Nuciforo P, et al. CelTIL score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial. SABCS 2020, Abstract PS5-03.
     
  • Mayer I, Farooki A, Rugo HS, et al. Early intervention for and management of alpelisib (ALP)-induced hyperglycemia: case studies from the Phase III SOLAR-1 trial. SABCS 2020, Abstract PS10-35.
     
  • Rugo HS, Tolaney SM, Loirat D, et al. Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients (pts) with metastatic triple-negative breast cancer (mTNBC). SABCS 2020, Abstract PS11-09.
     
  • Geyer, Jr CE, Untch M, Prat A, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: a randomized, phase 3 trial (DESTINY-Breast05). SABCS 2020, Abstract OT-03-01.

     

DGGG: 63. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe 2020, October 7-9, 2020, Virtual Meeting

  • Riecke K, Müller V, Neunhöffer T, et al. Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry – comparison of three different prognostic scores. oral presentation.

EBCC: European Breast Cancer Conference 2020, October 2-3, 2020, Virtual Meeting

  • Nuciforo P, Townend J, Saura C et al. Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial. Eur J Cancer 2020; Vol 138, S15-S16, oral presentation.
  • Rugo H, Cristofanilli M, Loibl S, et al. Predictors of efficacy in patients (pts) with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Subgroup analyses of PALOMA-3. Eur J Cancer 2020; Vol 138, S7-S8, oral presentation.
  • Laakmann E, Witzel I, Neunhöffer T, et al. Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases. Eur J Cancer 2020; Vol 138, S19, poster.

ESMO: European Society for Medical Oncology, September 19-21, 2020, Virtual Meeting

  • Schneeweiss A, Möbus V, Tesch H, et al. Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC). Ann Oncol 2020; Vol. 31, Suppl.4, S303-S304, oral presentation.
  • Mayer EL, Gnant MI, DeMichele A, et al. PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer. Ann Oncol 2020; Vol. 31, Suppl.4, S1145, oral presentation (proffered paper).
  • André F, Ciruelos EM, Juric D, et al. Overall Survival (OS) Results From SOLAR-1, a Phase 3 Study of Alpelisib (ALP) + Fulvestrant (FUL) for Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Advanced Breast Cancer (ABC). Ann Oncol 2020; Vol. 31, Suppl.4, S1142-S1215, oral presentation.
    Link T, Blohmer J-U, Just M, et al. GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status. Ann Oncol 2020; Vol. 31, Suppl.4, S308-S309, minioral presentation.
  • Hauke J, Ernst C, Fasching PA, et al. Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332). Ann Oncol 2020; Vol. 31, Suppl.4, S313, poster.
  • Rugo HS, Cristofanilli M, Loibl S, et al. Prognostic Factors for Overall Survival in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Analyses From PALOMA-3. Ann Oncol 2020; Vol. 31, Suppl.4, S372-S373, poster.
  • Loibl S, Rastogi P, Seiler S, et al. A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze). Ann Oncol 2020; Vol. 31, Suppl.4, S339, TIP.
     

AACR: American Association for Cancer Research, Annual Meeting June 22-24, 2020, Virtual Meeting

  • Benelli M, Biagioni C, Fimereli D, et al. Characterization of gene fusions in paired primary and metastatic samples of breast cancer in the AURORA molecular screening program. Cancer Res 2020;80(16 Suppl):Abstract nr 2488, poster.

ASCO: American Society of Clinical Oncology, Annual Meeting May 29-30, 2020, Virtual Meeting

  • Denkert C, Lambertini C, Fasching PA, et al. Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. J Clin Oncol.2020; 38.15_suppl.502, oral presentation.
  • Moebus V, Lueck HJ, Ladda E, et al. GAIN-2: Neo-/adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS). J Clin Oncol.2020; 38.15_suppl.516, poster discussion.
  • Rediti M, Venet D, Rothe F, et al. Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial. J Clin Oncol. 2020; 38.15_suppl.511, poster discussion.
    Cui W, Francis PA, Loi S, et al. Assessment of ovarian function as an endpoint in breast cancer clinical trials: A systematic review. J Clin Oncol.2020; 38. 15_suppl. e14098, session publication only.
  • Wimberger P, Blohmer J-U, Krabisch P, et al. Influence of denosumab on disseminated tumor cells (DTC) in the bone marrow of breast cancer (BC) patients with neoadjuvant treatment: A GeparX translational substudy. J Clin Oncol.2020; 38.15_suppl.580, poster.
  • Kolberg HC, Kühn T, Krajewska M, et al. Factors associated with axillary conversion after neoadjuvant chemotherapy in initially node positive breast cancer patients: A transSENTINA analysis. J Clin Oncol.2020; 38.15_suppl.557, poster.
     

ESMO-Breast Cancer May 23-24, 2020, Virtual Meeting

  • Loibl S, Huang CS, Mano MS, et al. Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE. Ann Oncol. 2020; Vol 31, S48, oral presentation.
  • Karn T, Denkert C, Weber K, et al. Tumour mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol 2020, Vol. 31, S58, oral presentation.
  • Curigliano G, Murthy R, Loi R, et al. Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). Ann Oncol 2020; Vol. 31, Suppl.4, S62-S63, oral presentation.
  • Reinisch M, Untch M, Reimer T, et al. Patients (pts) preference for different administration methods of trastuzumab (T) in pts with HER2+ early breast cancer (BC) treated within the GAIN-2 trial. Ann Oncol 2020, Vol. 31, S44, poster.
  • Riecke K, Mueller V, Neunhöffer T, et al. Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different prognostic scores. Ann Oncol 2020, Vol. 31, S70, poster.
     

DKK: 34. Deutsche Krebskongress 2020, February 19-22, 2020, Berlin Germany

  • Furlanetto J, Nekljudova V, Schneeweiss A, et al. Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC). DKK 2020, oral presentation.
  • Furlanetto J, Möbus V, Schneeweiss A, et al. Germline (g)BRCA1/2 mutations (m) and hematological toxicities in patients (pts) with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT). DKK 2020, poster.
     
  • Pohl-Rescigno E, Hauke J, Rhiem K, et al. Germline mutation status and therapy response in high-risk early-stage breast cancer: A secondary analysis of the GeparOcto randomized clinical trial (NCT02125344). DKK 2020, poster.
     
  • Tesch H, Loibl S, Kast K, et al. Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study. DKK 2020, poster.
     
  • Seiler S, Schmatloch S, Reinisch M, et al. Cancer Management and Outcome of young patients (pts) with breast cancer (BC) diagnosed at 40 years (yrs) or younger. DKK 2020, poster. 
     
  • Loibl S, Jackisch C, Seiler S, et al. Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with Atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of Atezolizumab/Placebo (GeparDouze). DKK 2020, TIP.
  • Golshan M, Loibl S, Wong SM, Houber JB, O'Shaughnessyet J al. Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial JAMA Surg. 2020;doi:10.1001/jamasurg.2019.5410 (2019 online ahead of print).
  • Papakonstantinou A, Matikas A, Bengtsson NO, Malmström P, Hedayati E et al. Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial. Cancer. 2019;doi:10.1002/cncr.32653. 
     
  • Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet. 2019;doi:10.1016/S0140-6736(19)32955-1. 
     
  • Sinn BV, Weber KE, Schmitt WD, Fasching PA, Symmans WF, et al. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Res. 2019;21:142. 
     
  • Witzel I, Loibl S, Wirtz R, Fasching PA, Denkert C, et al. Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. Br J Cancer. 2019 2019;121:1009–1015. 
     
  • Heitz F, Kümmel S, Lederer B, Solbach C, Engels K, Ataseven B, Sinn B, Blohmer JU, Denkert C, Barinoff J, Fisseler-Eckhoff A, Loibl S. Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. Geburtshilfe Frauenheilkd. 2019;79:1110-1117. 
     
  • Hui R, Pearson A, Cortés J, Campbell C, Poirot C, et al. Lucitanib for the treatment of HR(+)/ HER2(-) metastatic breast cancer: results from the multicohort phase II FINESSE study. Clin Cancer Res. 2019;doi:10.1158/1078-0432.CCR-19-1164. 
     
  • Golshan M, Wong SM, Loibl S, Huober JB, O'Shaughnessy J, et al. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. Eur J Surg Oncol. 2019;doi:10.1016/j.ejso.2019.10.002 
     
  • Papakonstantinou A, Hedayati E, Hellström M, Johansson H, Gnant M, et al. Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. Acta Oncol. 2020;59:75–81 (2019 online ahead of print).
  • Banys-Paluchowski M, Loibl S, Witzel I, Mundhenke C, Lederer B, et al. Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial. Cancers (Basel). 2019;11:1186. 
     
  • Krug D, Lederer B, Seither F, Nekljudova V, Ataseven B, et al. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. Ann Surg Oncol. 2019;26:3892-3901. 
     
  • Kümmel A, Kümmel S, Blohmer JU, Faridi A, Nitz U, et al. Autologous Lipotransfer - Daily Therapeutic Practice in Breast Cancer: An Intergroup Analysis Encompassing NOGGO, WSG, GBG, AWO Gyn and DGPRÄC. Breast Care (Basel). 2019;14:165-169. 
     
  • Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, et al. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Eur J Cancer. 2019;117:91-98. 
     
  • Furlanetto J, von Minckwitz G, Lederer B, Möbus V, Schneeweiss A, et al. Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. Breast Cancer. 2019;26:826-834. 
     
  • Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;doi: 10.1093/annonc/mdz158. 
     
  • Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, et al. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. J Clin Oncol. 2019;37:2226-2234. 
     
  • Laakmann E, Witzel I, Fasching PA, Rezai M, Schem C, et al. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Res. 2019;21:60. 
     
  • Noske A, Möbus V, Weber K, Schmatloch S, Weichert W, et al. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study. Eur J Cancer. 2019;114:76-88. 
     
  • Denkert C, Budczies J, Regan MM, Loibl S, Dell'Orto P, et al. Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. Breast Cancer Res Treat. 2019;176:557-568. 
     
  • Kuemmel S, Holtschmidt J, Gerber B, Von der Assen A, Heil J, et al. Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial. J Clin Oncol. 2019;37:1490-1498. 
     
  • Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, et al. Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. Clin Cancer Res. 2019;25:3986-3995. 
     
  • Lambertini M, Di Maio M, Poggio F, Pagani O, Curigliano G, et al. Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients. Reprod Biomed Online. 2019; 38:835-844. 
     
  • Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, et al. Genome-wide association study of germline variants and breast cancer-specific mortality. Br J Cancer. 2019;120:647-657. 
     
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393:1440-1452. 
     
  • Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, et al. Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. Int J Cancer. 2019;145:857-868. 
     
  • Eggemann H, Bernreiter AL, Reinisch M, Loibl S, Taran FA et al. Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis. Br J Cancer. 2019;120:301-305. 
     
  • Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet. 2019;104:21-34. 
     
  • Shu X, Wu L, Khankari NK, Shu X-O, Wang TJ et al. (Breast Cancer Association Consortium). Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. Int J Epidemiol. 2019;48:795–806. 
     
  • Froehlich K, Schmidt A, Heger JI, Al-Kawlani B, Aberl CA, Jeschke U, Loibl S, Markert UR. Breast cancer, placenta and pregnancy. Eur J Cancer. 2019;115:68-78. Review.

SABCS: San Antonio Breast Cancer Simposium, December 10-14, 2019, San Antonio, Texas, USA

  • van Mackelenberg M, Seither F, Möbus V et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. SABCS 2019; GS1-07, oral presentation.
  • Williams T, Schneeweiss A, Jackisch C et al. Caveolin gene expression predicts for response and clinical outcomes of patients treated with preoperative paclitaxel-based chemotherapy regimens in early stage breast cancer. SABCS 2019; P1-10-01, poster.
  • Blohmer J, Link T, Kümmel S et al. Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer - First results of the GeparX study. SABCS 2019; GS3-01, oral presentation.
  • Fasching PA, Denkert C, Benz S et al. Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - an analysis of the GeparSepto trial. SABCS 2019; PD5-08, poster discussion.
  • Fröhlich K, Plösch T, Seither F et al. Histological and epigenetic analyses of placenta tissue from breast cancer patients and healthy participants. SABCS 2019; P4-04-08, poster.
  • Loibl S, Untch M, Buyse M et al. Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC). SABCS 2019; P5-06-02, poster.
  • Szeto C, Denkert C, Fasching PA et al. Landscape of immune-cell signatures in early high-risk breast cancer (BC) reveals clinically-relevant enrichment of immune subpopulations. SABCS 2019;P6-10-04, poster.
  • Furlanetto J, Möbus V, Schneeweiss A et al. Germline (g)BRCA1/2 mutations (m) and hematological toxicities in patients (pts) with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT). SABCS 2019;P6-10-03, poster.
  • Piccart M, Procter M, Fumagalli D et al. Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. SABCS 2019;GS1-04, oral presentation.
  • Cuzick J, Sestak I, Forbes J et al. (IBIS-II investigators). Ten year results of the international breast cancer intervention study II. SABCS 2019;GS4-04, oral presentation.
  • Mano MS, Loibl S, Mamounas EP et al. Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis. SABCS 2019;P3-14-01, poster.
  • Geyer CE Jr, Loibl S, Rastogi P et al. A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze. SABCS 2019;OT2-04-08, poster.
  • Jerusalem G, Farah S, Chirgwin J et al. Sole (study of letrozole extension), a phase 3 randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (bc): final analysis and sole estrogen substudy (sole-est). SABCS 2019; P5-12-01, poster.

DGP: 103. Jahrestagung der Deutschen Gesellschaft für Pathologie, June 13-15 2019, Frankfurt am Main, Germany

  • Sinn BV, Loibl S, Karn T et al. Expression von PD-L1 und dynamische Veränderungen tumor-infiltrierender Lymphozyten bei neoadjuvanter Chemotherapie mit Immun-Checkpunkt-Blockade beim frühen triple-negativen Mammakarzinom. DGP 2019, AG05.02, oral presentation.

ESMO: European Society for Medical Oncology, September 27-October 1, 2019 Barcelona, Spain

  • Furlanetto J, Nekljudova V, Schneeweiss A et al. Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC). Ann Oncol 2019;Volume 30, Issue Suppl_5, 180PD, poster discussion.
  • Marmé F, Solbach C, Michel L et al. Utility of the CPS+EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. Ann Oncol 2019;Volume 30, Issue Suppl_5, 182PD, poster discussion.
  • Werutsky G, Untch M, Hanusch C et al. Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials. Ann Oncol 2019;Volume 30, Issue Suppl_5, 188P, poster.
  • Tesch H, Loibl S, Kast K et al. Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study. Ann Oncol 2019;Volume 30, Issue Suppl_5, 195P, poster.
  • Untch M, Geyer C, Huang C et al. Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: an update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC). Ann Oncol 2019;Volume 30, Issue Suppl_5, LBA19, oral presentation.

DGS: Deutsche Gesellschaft für Senologie 39. Jahrestagung, June 27-29, 2019 Berlin, Germany

  • Banys-Paluchowski M, Loibl S, Witzel I et al. Clinical relevance of collagen protein degradation markers C3M and C4M in the serum of breast cancer patients treated with neoadjuvant therapy in the GeparQuinto trial. DGS 2019, #094, poster.
  • Reimer T. Update NSEMA-Studie. DGS 2019; oral presentation.

ASCO: American Society of Clinical Oncology, Annual Meeting May 31-4 June, 2019, Chicago, IL, USA

  • Denkert C, Link T, Jank P et al. Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial. J Clin Oncol 2019;37.15_suppl.3075, poster.
  • Loibl S, Sinn BV, Karn T et al. Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial. J Clin Oncol 2019;37.15_suppl.509, poster discussion.
  • Seliger B, Karn T, Denkert C et al. Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial. J Clin Oncol 2019;37.15_suppl.588, poster.
  • Pohl-Rescigno E, Hauke J, Rhiem K et al. Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344). J Clin Oncol 2019;37.15_suppl.573, poster.
  • Fasching PA, Jackisch C, Rhiem K et al. GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD). J Clin Oncol 2019;37.15_suppl.506, oral presentation.
  • Geyer CE, Loibl S, Rastogi P et al. NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. J Clin Oncol 2019;37.15_suppl.TPS605, poster.
  • Krop IE, Paulson J, Campbell C et al. Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial. J Clin Oncol 2019;37.15_suppl.1012, oral presentation.
  • Schneeweiss A, Loib S, Mamounas EP et al. Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. J Clin Oncol 2019;37.15_suppl.513, poster discussion.
  • Metzger O, Stover DG, Asad S et al. Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study. J Clin Oncol 2019; 37.15_suppl.510, poster discussion.

ESMO-Breast Cancer 2019, May 2-4, 2019 Berlin, Germany

  • Huober J, Schneeweiss A, Blohmer JU et al. Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: pooled analysis based on the GBG database. Ann Oncol 2019; 30 (suppl_3): iii34-iii38; #1080, oral presentation.
  • Jank P, Loibl S, Fasching PA et al. Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: pooled analysis of 484 patients from three prospective multicentre GBG trials. Ann Oncol 2019; 30 (suppl_3): iii1-iii26, #15P, poster.
  • Loibl S, Jackisch C, Rastogi P et al. GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. Ann Oncol 2019; 30 (suppl_3): iii34-iii38, #122TiP, poster.
  • Denkert C, Link T, Jank P et al. (on behalf of the GBG neoadjuvant and translational subboard). Expression of ER, PR, HER2 and Ki-67 in the neoadjuvant GeparX trial - comparison of central immunohistochemistry (IHC) with an automated cartridge-based system for mRNA assessment. Ann Oncol 2019; 30 (suppl_3): iii1-iii26, #25P, poster.
  • Karn T, Denkert C, Weber KE. et al. Para-necrotic expression of VEGFA metagene signature identified by single-cell profiling. Ann Oncol 2019; 30 (suppl_3): iii1-iii26, #9O, poster discussion.
  • Schneeweiss A, Möbus V, Tesch H, Hanusch C, Denkert C, et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer. 2019 (manuscript accepted 2018);106:181-192.
  • Bischoff J, Barinoff J, Mundhenke C, Bauerschlag DO, Costa S-D, et al. A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). Anti-Cancer Drugs 2018 (manuscript accepted 2018).
  • von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2018 Dec 5. [Epub ahead of print] 
  • Matikas A, Foukakis T, Moebus V, Greil R, Bengtsson NO, et al. Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: Further results from the prospective PANTHER study with focus on obese patients. Ann Oncol. 2018 Oct 24 [Epub ahead of print] 
     
  • Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, et al. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. J Clin Oncol. 2018; 36:1981-1990 
     
  • Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response - final results from GeparSixto. Ann Oncol. 2018;29:2341-2347.
  • Liedtke C, Kolberg HC, Kerschke L, Görlich D, Bauerfeind I, et al. Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST). Clin Exp Metastasis. 2018;35:777-783.
  • Stevic I, Müller V, Weber K, Fasching PA, Karn T, et al. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med. 2018;16:179.
  • Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, et al; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018; 379:122-137
  • Lambertini M, Di Maio M, Pagani O, Curigliano G, Poggio F, et al. The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast. 2018;42:41-49
  • Witzel I, Laakmann E, Weide R, Neunhöffer T, Park-Simon TJ, et al. Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. Eur J Cancer. 2018;102:1-9.
  • Nekljudova V, Loibl S, von Minckwitz G, Schneeweiss A, Glück S, et al. Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC). Contemp Clin Trials. 2018 71:194-198.
  • Wu L, Shi W, Long J, Guo X, Michailidou K, et al. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nat Genet. 2018; 50:968-978. 
     
  • Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, et al. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol. 2018; 36:2281-2287.
  • von Waldenfels G, Loibl S, Furlanetto J, Machleidt A, Lederer B, et al. Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Oncotarget. 2018;9(20):15168-15179.
  • Loibl S, Weber K, Huober J, Krappmann K, Marmé F, et al. Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinico-molecular predictor. Clin Cancer Res. 2018; 24:3358-3365.
  • Untch M, von Minckwitz G, Gerber B, Schem C, Rezai M, et al. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). J Clin Oncol. 2018; 36:1308-1316. 
     
  • Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, et al. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer. 2018; 18:265
  • Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018; 19:497-509. 
     
  • Ingle JN, Kalari KR, Wickerham DL, von Minckwitz G, Fasching PA, et al. Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. Pharmacogenet Genomics. 2018;28:147-152.
  • Möbus V, Jackisch C, Lück HJ, du Bois A, Thomssen C, et al. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol. 2018;29:178-185.
  • Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. J Natl Cancer Inst. 2018; 110:560-567.

Reviews

  • Denkert C, Loibl S, Budczies J, Wienert S, Klauschen F. [Standardized determination of tumor-infiltrating lymphocytes in breast cancer : A prognostic marker for histological diagnosis]. Der Pathologe. 2018; 39:520-531.
  • Klauschen F, Müller KR, Binder A, Bockmayr M, Hägele M, et al. Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. Semin Cancer Biol. 2018;52(Pt 2):151-157. 
     
  • Tancredi R, Furlanetto J, Loibl S. Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature. Oncologist. 2018; 23:974-981. 
     
  • Duchnowska R, Loibl S, Jassem J. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treat Rev. 2018;67:71-77.

Mitglieder der German Breast Group präsentierten im Jahr 2018 folgende Beiträge auf internationalen Kongressen:

SABCS: San Antonio Breast Cancer Simposium, 4-8 December 2018, San Antonio, Texas, USA 
 

  • Geyer Jr. CE, Huang C-S, Mano MS, Loibl S, Mamounas EP, et al. Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE. SABCS 2018; GS1-10, oral presentation.
  • Loibl S, Sinn BV, Karn T, Untch M, Treue D, et al. mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)- Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial. SABCS 2018; PD5-13, poster discussion.
  • Sinn BV, Loibl S, Karn T, Untch M, Kunze CA, et al. Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial. SABCS 2018; PD5-05, poster discussion.
  • Seiler S, Schmatloch S, Reinisch M, Neunhöffer T, Schmidt M, et al. Cancer management and outcome of very young non-pregnant patients with breast cancer diagnosed at 40 years or younger– GBG 29. SABCS 2018; P1-17-07, poster.
  • Huober J, Schneeweiss A, Blohmer J-U, Denkert C, Tesch H, et al. Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy – Results of a pooled analysis based on the GBG meta-database. SABCS 2018; P2-08-01, poster.
  • Villegas SL, Lederer B, Untch M, Holms F, Ulmer H-U, et al. Similarities between low hormone receptor positive and hormone receptor negative breast cancer: An analysis of 4366 patients from multicenter clinical trials. SABCS 2018; P2-08-10, poster.
  • Karn T, Denkert C, Sinn BV, Weber K, Nekljudova V, et al. Single-cell profiling identifies hypoxic carcinoma cells as source of an immunosuppressive VEGFA metagene. SABCS 2018; P3-10-01, poster.
  • Massa C, Schneeweiss A, Karn T, Hanusch CA, Blohmer J-U, et al. Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy with durvalumab - Results from the prospectively randomized GeparNuevo trial. SABCS 2018; P4-06-01, poster.
  • Witzel ID, Riecke K, Laakmann E, Weide R, Neunhoeffer T, et al. Validation of different prognostic scores in breast cancer patients with brain metastases of the BMBC registry (GBG-79). SABCS 2018; P4-08-26, poster.
  • Finn RS, Turner NC, Liu Y, Rugo HS, Loibl S, et al. Biomarker analysis of CDK 4/6 and endocrine pathways in hormone-receptor positive (HR+) advanced breast cancer (ABC) bone only disease patients: A joint analysis of PALOMA-2 and PALOMA-3 studies. SABCS 2018; P6-18-03, poster.
  • Metzger O, Mandrekar S, Loibl S, Mundhenke C, Seiler S, et al. PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). SABCS 2018; OT3-02-07, poster.
  • Geyer, Jr. CE, Loibl S, Rastogi P, Seiler S, Costantino JP, et al. A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze. SABCS 2018; OT3-05-01, poster.
  • Ignatiadis M, McArthur H, Bailey A, Martinez J-L, De Azambuja E, et al. ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer. SABCS 2018; OT3-05-02, poster.
  • O'Leary B, Lira ME, Huang S, Deng S, Xie T, et al. Longitudinal ctDNA sequencing using an expanded genomic panel in the PALOMA3 trial of palbociclib plus fulvestrant. SABCS 2018; PD2-02, poster discussion.
  • Polley M-YC, Dickler MN, Johnston S, Goetz MP, de la Haba J, et al. A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy. SABCS 2018; P2-07-05, poster.

ESMO: European Society for Medical Oncology, 19-23 October, 2018, Munich, Germany

  • Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B et al. Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). Ann Oncol 2018;29, suppl_8, mdy270.185, 188PD, poster discussion.
  • Reinisch M, Seiler S, Hauzenberger T, Schmatloch S, Strittmatter H-J, et al. Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients. Ann Oncol 2018;29, suppl_8, mdy424.007, 273PD_PR, poster discussion.
  • Fasching PA, Laible M, Weber KE, Wirtz RM, Denkert C, et al. Validation of the MammaTyper® pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC). Ann Oncol 2018;29, suppl_8, mdy269.166, 168P, poster.
  • Fasching PA, Laible M, Weber KE, Wirtz RM, Denkert C, et al. Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes. Ann Oncol 2018;29, suppl_8, mdy270.222, 227P, poster.
  • Pohl E, Schneeweiss A, Hauke J, Moebus V, Furlanetto J et al. Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. Ann Oncol 2018;29, suppl_8, mdy270.238, 243P, poster.
  • Loibl S, Metzger O, Mandrekar S J, Mundhenke C, Seiler S et al. PATINA: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy (ET) vs. Anti-HER2 Therapy + ET after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer (MBC). Ann Oncol 2018;29, suppl_8, mdy272.357, 369TIP, poster.
  • Decker T, Denkert C, Lübbe K, Müller V, Mundhenke C, et al. Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97. Ann Oncol 2018;29, suppl_8, mdy272.352, 364TiP, poster.
  • Cristofanilli M, Slamon DJ, Ro J, Bondarenko I, Im S-A, et al. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. Ann Oncol 2018;29, suppl_8, mdy424.009, LBA2_PR, poster.
  • Lambertini PM, Maio MD, Poggio F, Pagani O, Curigliano G, et al. Physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey. Ann Oncol 2018;29, suppl_8, mdy300.009, 1692P, poster.
  • Hui R, Pearson A, Cortes Castan J, Campbell C, Poirot C, et al. Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial. Ann Oncol 2018;29, suppl_8, mdy272.281,289PD, poster discussion.
  • Day C, Middleton D, Loibl S. Application of CDK4/6 inhibitors in practice: Effect of online education on clinician competence and confidence. Ann Oncol 2018;29, suppl_8, 343P, poster.

ECI: 5th European Congress of Immunology, 2-5 September, 2018 Amsterdam, Netherlands

  • Massa C, Mueller A, Schneeweiss A, Hanusch C, Huober J, et al. Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial). ECI 2018;P.B1.03.10, poster.

DGS (Deutsche Gesellschaft für Senologie), 38 Jahrestagung, June 14-16, Stuttgart, Germany

  • Thill M, Seiler S, Decker T et al. A randomized, open-label, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment in patients with hormone receptor-positive, HER2-negative metastatic breast cancer (PADMA); poster
  • Decker T, Barinoff, J, Furlanetto J et al. Anti-hormonal maintenance treatment with/without the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in HR+/HER2- metastatic breast cancer: a phase II trial (AMICA) GBG 97; poster
  • Kümmel S, von Minckwitz G, Vladimirova V et al. Investigating Denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX); poster
  • Loibl S, Jackisch C, Seiler S et al. A randomized, double-blind, phase III trial of neoadjuvant chemotherapy with Atezolizumab/Placebo in patients with triple-negative breast cancer followed by adjuvant continuation of Atezolizumab/Placebo (GeparDouze); poster
  • Furlanetto J, Thode C, Huober J et al. Changes in hormone levels (E2, FSH, AMH) and fertility of young women treated with neo-/adjuvant chemotherapy (CT) for early breast cancer (EBC); poster
  • Noske A. Tumor infiltrating lymphocytes predict better DFS from intense dose-dense (idd) EPC regimen - results from the German Adjuvant Intergroup Node-positive Study (GAIN-1); oral presentation
  • Reinisch M. Erste Daten der MALE Studie: Welche Hormontherapie ist die effektivste beim Mann?; oral presentation
  • Reimer T. Update INSEMA-Studie; oral presentation

ASCO, June 1-5, Chicago, USA

  • Loibl S, Untch M, Burchardi N et al. Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). J Clin Oncol 36, 2018 (suppl; abstr 104); oral presentation.
  • Möbus V, Noeding S, Ladda E et al. Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting. J Clin Oncol 36, 2018 (suppl; abstr 568); poster.
  • Kümmel S, Wimberger P, von Minckwitz G et al. Investigating denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules: 2x2 factorial design (GeparX)—An interim safety analysis. J Clin Oncol 36, 2018 (suppl; abstr 569); poster.
  • Geyer CE, Loibl S, Rastogi P et al. NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. J Clin Oncol 36, 2018 (suppl; abstr TPS603); poster.
  • Telli M L, Metzger O, Timms K et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. J Clin Oncol 36, 2018 (suppl; abstr 519); poster discussion.
  • Matikas A, Foukakis T, Möbus V et al. Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study. J Clin Oncol 36, 2018 (suppl; abstr 538); poster. 
     
  • Noske A, Weber K, Möbus V et al. Tumor infiltrating lymphocytes to predict DFS from intense dose-dense (idd) EPC regimen: Results from the German Adjuvant Intergroup Node-positive study (GAIN-1). J Clin Oncol 36, 2018 (suppl; abstr 527); poster.
  • Guerini-Rocco E, Gray K P, Munzone E et al. Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the “SOLE” trial. J Clin Oncol 36, 2018 (suppl; abstr 517); poster discussion.
    Denkert C, Untch M, Benz SC et al. Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer: A genome-based investigation in the neoadjuvant GeparSepto trial. J Clin Oncol 36, 2018 (suppl; abstr 574); poster.
  • Kolberg H-C, Liedtke C, Bauerfeind I et al. Association of clinical/pathological parameters with axillary involvement in early breast cancer in patients with limited sentinel node involvement after neoadjuvant chemotherapy (NACT). J Clin Oncol 36, 2018 (suppl; abstr 559); poster.

AACR, Apr 14-18, Chicago, USA

  • Loibl S, Treue D, Budczies J, Weber K., Stenzingeret A et al. Mutational diversity and therapy response in breast cancer - a sequencing analysis in the neoadjuvant GeparSepto trial. Cancer Res 2018;78(13 Suppl):Abstract nr LB-027; poster

Pfitzner BM, Lederer B, Lindner J, Solbach C, Engels K, et al. Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years. Mod Pathol. 2017 Dec 22. [Epub ahead of print]. 

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2017 Dec 11. [Epub ahead of print]. 

Han SN, Amant F, Cardonick EH, Loibl S, Peccatori FA, et al. Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. Breast Cancer Res Treat. 2017 Dec 12. [Epub ahead of print]. 

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2017 Dec 7 [Epub ahead of print]. 

Villegas SL, Darb-Esfahani S, von Minckwitz G, Huober J, Weber K, et al. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2017 Nov 25 [Epub ahead of print]. 

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Nov 17 [Epub ahead of print]. 

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377:1836-1846.

Schirm S, Engel C, Loibl S, Loeffler M, Scholz M. Model-based optimization of G-CSF treatment during cytotoxic chemotherapy. J Cancer Res Clin Oncol. 2017; [Epub ahead of print]. 

Criscitiello C, Bayar MA, Curigliano G, Symmans FW, Desmedt C, et al. A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer. Ann Oncol. 2017; [Epub ahead of print]. 

Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, et al. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017; 551:92-94. 


Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017;49:1767-1778.

Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, et al. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). Eur J Cancer. 2017;85:133-145. 

van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, et al. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Res Treat. 2017 Sep 5. [Epub ahead of print]. 

van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, et al. BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial. Breast Cancer Res Treat. 2017; 166:775-785. 

Kümmel S, Paepke S, Huober J, Schem C, Untch M, et al. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Eur J Cancer. 2017;84:1-8.

Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol. 2017; 3:1378-1385. 

Maetens M, Brown D, Irrthum A, Aftimos P, Viale G, et al. The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group. NPJ Breast Cancer. 2017;3:23. 

Riethdorf S, Müller V, Loibl S, Nekljudova V, Weber K, et al. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clin Cancer Res. 2017;23:5384-5393. 

Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, et al. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Oncologist. 2017; 22:1028-1038.

Möbus V, von Minckwitz G, Jackisch C, Lück HJ, Schneeweiss A, et al. A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients. Ann Oncol. 2017; 28:1803-1810. 

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017; 377:122-131.

Reimer T, Stachs A, Nekljudova V, Loibl S, Hartmann S, et al. Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial. Geburtshilfe Frauenheilkd. 2017;77:149-157.

Furlanetto J, Jackisch Ch, Untch M, Schneeweiss A, Schmatloch S, et al. Efficacy and safety of nab-paclitaxel 125 mg/m2 and nabpaclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69). Breast Cancer Res Treat. 2017;163(3): 495-506. 

Reinisch M, Huober J, von Minckwitz G, Blohmer JU, Denkert C, et al. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. Breast. 2017;32:73-78.

Reviews

Mamounas EP, Kuehn T, Rutgers EJT, von Minckwitz G. Current approach of the axilla in patients with early-stage breast cancer. Lancet 2017 Aug 14. [Epub ahead of print].

Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389:2430-2442. 

Hendry S, Salgado R, Gevaert T, Russell PA, John T, et al. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol. 2017;24:235-251.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, et al. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol. 2017;24:235-251.

Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017;Ann Oncol. 2017; 28:1700-1712.

Mitglieder der German Breast Group präsentierten im Jahr 2017 folgende Beiträge auf internationalen Kongressen:

SABCS, San Antonio, USA

Sinn BV, Weber K, Denkert C, Fasching PA, Schmitt WD, Thomas K, Ingold-Heppner B, van Mackelenbergh M, Symmans WF, Marmé F, Taube E, Müller V, Kunze CA, Schem C, Pfitzner BM, Stickeler E, von Minckwitz G, Loibl S. HLA class I expression is associated with tumor-infiltrating lymphocytes and response and survival after neoadjuvant chemotherapy in hormone receptor-positive, HER2-negative breast cancer. SABCS 2017; P1-07-01.

Witzel ID, Laakmann E, Fasching PA, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Zahm D, Blohmer J, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Müller V, Loibl S.Development of brain metastases in breast cancer patients treated in the neoadjuvant trials Geparquinto and Geparsixto. SABCS 2017; P1-17-01.

Karn T, Meissner T, Weber K, Sinn B, Denkert C, Budczies J, Nekljudova V, Fasching PA, Holtrich U, Schem C, Solbach C, Hartmann A, Röcken C, Untch M, Young BM, Willis S, Leyland-Jones B, von Minckwitz G, Loibl S. Blinded molecular subtyping analysis from RNA-Seq of FFPE samples in the GeparQuinto trial reveals predictive value of VEGFA metagene for bevacizumab treatment. SABCS 2017; P2-09-02.

Möbus V, Mahlberg R, Janni W, Tomé O, Marmé F, Forstbauer H, Reimer T, von der Assen A, Reinisch M, Lorenz R, Schmatloch S, Schmidt M, Sinn B, Klutinus N, Stickeler E, Untch M, Seiler S, Burchardi N, von Minckwitz G, Loibl S. Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study. SABCS 2017; P5-20-09.

von Waldenfels G, Loibl S, Furlanetto J, Machleidt A, Lederer B, Denkert C, Hanusch C, Huober J, Jackisch C, Kümmel S, von Minckwitz G, Schneeweiss A, Untch M, Rhiem K, Fasching PA, Blohmer JU. Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials. SABCS 2017; P6-15-03.

Furlanetto J, Thode C, Huober J, Denkert C, Bassy M, Hanusch C, Jackisch C, Kümmel S, Schneeweiss A, Untch M, Fasching PA, Karn T, Marmé F, van Mackelenbergh M, Müller V, Schem C, von Minckwitz G, Strik D, Nekljudova V, Loibl S. Changes in hormone levels (E2, FSH, AMH) and fertility of young women treated with neoadjuvant chemotherapy (CT) for early breast cancer (EBC). SABCS 2017; PD7-09.

Reinisch M, Seiler S, Hauzenberger T, Schmatloch S, Strittmatter HJ, Zahm DM, Thode C, Jackisch C, Furlanetto J, Strik D, Stickeler E, Marmé F, Janni W, Schmidt M, Kamischke A, Rudlowski C, Nekljudova V, von Minckwitz G, Loibl S. Male-GBG54: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients. SABCS 2017; PD7-10.

Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Denkert C, Murray E, Grieve R, Coleman R, Schmidt M, Klare P, Rezai M, Rautenberg B, Klutinus N, Rhein U, Mousa K, Ricardo-Vitorino S, von Minckwitz G, Bliss J. A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn Celecoxib Trial). SABCS 2017; GS3-03.

Schneeweiss A, Jackisch C, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Rhiem K, Warm M, Fasching PA, Just M, Hanusch C, Hackmann J, Blohmer JU, Gerber B, Furlanetto J, von Minckwitz G, Nekljudova V, Loibl S, Untch M. Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline-cyclosphosphamide for patients with early breast cancer - GBG69. SABCS 2017; GS3-05.

Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L. Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients. SABCS 2017; GS4-01.

Loibl S, Barinoff J, Seiler S, Decker T, Denkert C, Hardy-Bessard A-C, Senkus-Konefka E, Cognetti F, Palmieri C, Gelmon K, Luebbe K, Furlanetto J, Mueller V, Mundhenke C, Schmidt M, von Minckwitz G, Uhlig M, Burchardi N, Thill M. A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA). SABCS 2017; OT3-05-04.

Metzger-Filho O, Mandrekar S, Loibl S, Ciruelos E, Gianni L, Lim E, Miller K, Huang C, Koehler M, Francis P, Valagussa P, Goel S, Prat A, Goetz M, Loi S, Krop I, Carey L, Lanzillotti J, Winer E, Tripathy D, DeMichele A. PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer. SABCS 2017; OT3-05-07.

Mayer E, DeMichele A, Gnant M, Barry W, Pfeiler G, Metzger O, Burstein H, Miller K, Rastogi P, Loibl S, Goulioti T, Zardavas D, Fesl C, Koehler M, Huang-Bartlett C, Huang X, Piccart M, Winer E, Wolff A. PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer. SABCS 2017; OT3-05-08.

ESMO, Madrid, Spain

Brandberg Y, Loibl S,. Foukakis T,. Johansson H, Gnant M,. Singer C.F, von Minckwitz G, Bengtsson N-O, Karlsson E, Mlineritsch B, Hellstro M,. Steger G, Carlsson L, Egle D, Greil R, Bergh J. CTCA toxicity scoring and EORTC quality of life questionnaire: A comparison of physicians’ and patients’ scoring of toxicity in the “Panther trial” Ann of Oncology 2017; Abstract nr 1422O, ESMO 2017, Madrid

Metzger O, Mandrekar S, Ciruelos E, Loibl S, Valagussa P, Demichele A.M, Lim E, Tripathy D,. Winer E, Huang C, Khoeler M, Carey L, Francis P, Miller K, Goel S, Goetz M.P, Prat A, Loi S. Krop I, Gianni L. PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer, Ann of Oncology 2017; Abstract nr 324TiP, ESMO 2017, Madrid

Dalvi T, Gelmon K.A, Dent R, Pegram M, Loibl S, Tazir Y, Milner A, Lewis J. BREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC). Ann of Oncology 2017; Abstract nr 316TiP, ESMO 2017, Madrid

Criscitiello C, Bayar M.A, Curigliano G, Symmans F, Desmedt C, Bonnefoi H, Sinn B, Pruneri G, Vicier C, Pierga J-Y, Denkert C, Loibl S, Sotiriou C, Michiels S, Andre´ F. A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracyclinebased neoadjuvant chemotherapy. Ann of Oncology 2017; Abstract nr 217O, ESMO 2017, Madrid

Mayer E.L,.DemicheleA.M, PfeilerG,. Barry W, Metzger O, Rastogi P, Symmans F, Burstein H.J, Miller K, Loibl S, Schmatloch S, Goulioti T, Zardavas D,. Fesl C, Koehler M, Bartlett C Huang, Huang X, Piccart M, E. Winer4, Gnant M. PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR1/HER2-early breast cancer. Ann of Oncology 2017; Abstract nr 215TiP, ESMO 2017, Madrid

Untch M,. Schneeweiss A, Salat C, Rezai M, Zahm D-M, Klare P,. Blohmer J-U, Tesch H, Khandan F, Fasching P.A.,Jackisch C, Nekljudova V, von Minckwitz G, Loibl SLong-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto) Ann of Oncology 2017; Abstract nr 163PD, ESMO 2017; Madrid

von Minckwitz G, Ponomarova O, Morales S, Zhang N, Hanes V. Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer. Annals of Oncology 28 (Supplement 5), 2017, Abstract nr 151PD, ESMO 2017, Madrid
Delaloge S, Ye Y, Cella D, Buyse M, Chan A, Barrios C,. Holmes F A, Mansi J,. Iwata H, Ejlertsen B, Moy B, von Minckwitz G, Chia S, Gnant M, Smichkoska S, Ciceniene A, Moran S, Auerbach A.H, Fallowfield L,. Jimenez M M. Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER21 breast cancer (BC): longitudinal analyses from the phase III ExteNET trial. Annals of Oncology 28 (Supplement 5), 2017, Abstract nr 177P, ESMO 2017, Madrid

Jimenez M M,. Holmes F.A,. Ejlertsen B, Delaloge S.,. Moy, B,. Iwata H,. von Minckwitz G,. Chia S, Mansi J,. Barrios C, Gnant M, Tomasevic Z,. Denduluri N, Separovic R, Kim S-B, Jakobsen E.H, Bryce R.P, Xu F, Buyse M, Chan A. Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER21 breast cancer (BC): 5-year analysis of the phase III ExteNET trial. Annals of Oncology 28 (Supplement 5), 2017, Abstract nr 149O, ESMO 2017, Madrid

IMPAKT, Brussels, Belgium

Loibl S, Pfarr N, Weber K, Neunhöffer T, Villegas S, Stenzinger A, Furlanetto J, Aktas B, Budczies J, Marmé F, Kahmann L, Denkert C, Weichert W. Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls. Cancer Res 2017;77(4 Suppl):Abstract nr P2-03-09, IMAKT Brussels.

ASCO, Chicago, USA

von Minckwitz G, Jennifer Procter M, De Azambuja E, Zardavas D, Knott A, Viale G,. Suter T M, Arahmani A, Rouchet N, Clark E, Benyunes M, Lang I, Levy C,. Yardley D A, Bines J,. Gelber R D,. Piccart-Gebhart M J, Baselga J. APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). J Clin Oncol 35, 2017 (suppl; abstr LBA500), ASCO 2017, Chicago

Golshan M, Loibl S, Huober J B, O'Shaughnessy J, Rugo H S, Wolmark N, McKee M D, Maag D, Sullivan D M, Giranda V L, Liu X, von Minckwitz G, Geyer C E, Sikov W M, ntch M. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess). J Clin Oncol 35, 2017 (suppl; abstr 514), ASCO 2017, Chicago

Loibl S, Untch M, Burchardi N, Huober J B, Blohmer J U, Grischke E-M, Furlanetto J, Tesch H, Hanusch C, Rezai M, Jackisch Ch, Schmitt W D, von Minckwitz G, Thomalla J, Kummel S, Rautenberg B, Fasching P A, Rhiem K, Denkert C, Schneeweiss A. A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). J Clin Oncol 35, 2017 (suppl; abstr 3062), ASCO 2017, Chicago

Schneeweiss A, Moebus V, Tesch H, Hanusch C, Denkert C, Luebbe K, Huober J B, Klare P, Kummel S, Untch M, Kast K, Jackisch Ch, Thomalla J, Heppner B I, Blohmer J U, Rezai M, Frank M, Nekljudova V, von Minckwitz G, Loibl S. A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). J Clin Oncol 35, 2017 (suppl; abstr 518), ASCO 2017, Chicago

Martin M, Loibl S, Hyslop T, de la Haba-Rodriguez J, Aktas B, Cirrincione C, Eva Maria M, Mehta K, Barry W T, Morales S, Carey L A, Saenz J A G, Partridge A, Martinez N, Hahn O M, Winer E P, Guerrero A, Hudis C, Casas M, Dickler M N. Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. J Clin Oncol 35, 2017 (suppl; abstr 1012), ASCO 2017, Chicago

Kummel S, Holtschmidt J, Gerber B, von der Assen A, Heil J, Thill M, Krug D, Schem Ch, Denkert C, Lubitz J, Blohmer J U, Hötzeld M, Seither F, Nekljudova V, Schwidde I, Uhrhan K, von Minckwitz G, Rezai M, Loibl S, Kuehn T. Randomized surgical multicenter trial to evaluate the usefulness of lymphoscintigraphy (LSG) prior to sentinel node biopsy (SLNB) in early breast cancer: SenSzi (GBG80) trial. J Clin Oncol 35, 2017 (suppl; abstr 555), ASCO 2017, Chicago

Bayar M-A, Criscitiello C, Curigliano G, Symmans W F, Desmedt Ch, Bonnefoi H R, Sinn B V, Pruneri G, Vicier C, Pierga J-Y, Denkert C, Loibl S, Sotiriou C, Michiels S, Andre F. A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 35, 2017 (suppl; abstr 575), ASCO 2017, Chicago

Anders C K, Murthy R K, Hamilton E P, Borges V F, Cameron D A, Carey L A, Müller V, Curigliano G, Gelmon K A, Hortobagyi G N, Krop I E, Loibl S, Pivot X B, Pegram M D, Slamon D J, Hurvitz S A, Tsai M L, Winer E P. A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB). J Clin Oncol 35, 2017 (suppl; abstr TPS1107), ASCO 2017, Chicago

Wroblewski M, Velthaus J-L, Bauer R, Müller V, Schem Ch, Fasching P A, Karn T, Fehm T N, Kühn T, Rack B K, Denkert C, Untch M, Kittel K, Janning M, Minner S, Sauter G, Bokemeyer C, von Minckwitz G, Loibl S, Loges S. Effect of mast cells on efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme b. J Clin Oncol 35, 2017 (suppl; abstr 11522), ASCO 2017, Chicago

Furlanetto J, Thode Ch, Bassy M, Denkert C, Hanusch C, Huober J B, Jackisch Ch, Kummel S, Schneeweiss A, Untch M, Fasching P A, Karn T, Marme F, van Mackelenbergh M, Müller V, Schem Ch, von Minckwitz G, Strik D, Nekljudova N, Loibl S. Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC). J Clin Oncol 35, 2017 (suppl; abstr 10068), ASCO 2017, Chicago

Liedtke C, Kolberg H-Ch, Kerschke L, Goerlich D, Bauerfeind I, Fehm T N, Fleige B, Hauschild M, Helms G, Lebeau A, Schmatloch S, Schrenk P, Schwentner L, Staebler A, von Minckwitz G, Loibl S, Untch M, Kuehn T. Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients converting from cN+ to ycN0 through primary systemic therapy (PST). J Clin Oncol 35, 2017 (suppl; abstr 560), ASCO 2017, Chicago

Loibl S, Barinoff J, Seiler S, Decker T, Denkert C, Luebbe K, Furlanetto J, Mueller V, Mundhenke C, Schmidt M, von Minckwitz G, Uhlig M, Burchardi N, Thill M. A randomized, open-label, multicentre, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy based treatment strategy in patients with hormone receptor positive/HER2-negative metastatic breast cancer in a real world setting. J Clin Oncol 35, 2017 (suppl; abstr TPS1115), ASCO 2017, Chicago

Loibl S, Werutsky G, Nekljudova V, Seiler S, Blohmer J U, Denkert C, Hanusch C, Huober J B, Jackisch Ch, Kummel S, Schneeweiss A, Untch M, Rhiem K, Fasching P A, von Minckwitz G, Furlanetto J. Impact in delay of start of chemotherapy and surgery on pCR and survival in breast cancer: A pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials. J Clin Oncol 35, 2017 (suppl; abstr 571), ASCO 2017, Chicago

Colleoni M, Luo W, Karlsson P, Chirgwin J H, Aebi S P, Jerusalem G H M, Neven P, Hitre E, Graas M-P, Simoncini E, Kamby C, Thompson A M, Loibl S, Gavilá J, Kuroi K, Gnant M, Rabaglio-Poretti M, Regan M M, Coates A S, Goldhirsch A. SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC). J Clin Oncol 35, 2017 (suppl; abstr 503), ASCO 2017 Chicago

Rugo H S, Andre F, Rubovszky G, Kaufman B, Inoue K, Takahashi M, Shimizu S, Ciruelos E M, Campone M, Conte P F, Iwata H, Loibl S, Mayer I A, Juric D, Longin A-S, Mills D, Wilke C, Sellami D B. A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1. J Clin Oncol 35, 2017 (suppl; abstr TPS1111), ASCO 2017 Chicago

Geyer C. E, O'Shaughnessy J, Untch M, Sikov W, Rugo H. S, McKee M. D, Huober J B, Golshan M, Giranda V L, von Minckwitz G, Maag D, Sullivan D M, Wolmark N, McIntyre K, Jose Juan Ponce Lorenzo J J P, Filho O M, Rastogi P, Symmans W F, Liu X, Loibl S Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC). J Clin Oncol 35, 2017 (suppl; abstr 520), ASCO 2017, Chicago

DGS (Deutsche Gesellschaft für Senologie), Berlin, Germany

Kümmel S, Holtschmidt J, Gerber B, Von der Assen A, Heil J, et al. Randomisierte, kontrollierte, multizentrische, operative Studie zur Evaluation der Rolle einer präoperativen Lymphszintigraphie vor axillärer Sentinel-Lymphonodektomie beim primären Mammakarzinom (SenSzi). Oral presentation, DGS 2017, Berlin 

Reimer T. INSEMA: Eine multizentrische, prospektive, randomisierte Studie zum Vergleich der axillären Wächterlymphknoten-Biopsie zu keiner axillären Operation bei Patientinnen mit frühem invasivem Brustkrebs und brusterhaltender Operation - Eine gemeinsame Studie der AGO-B, GBG, NOGGO, SUCCESS, WSG und der ABCSG, DGS 2017, oral presentation.

Foukakis T, von Minckwitz G, Bengtsson NO, Brandberg Y, Wallberg B, Fornander T, Mlineritsch B, Schmatloch S, Singer CF, Steger G, Egle D, Karlsson E, Carlsson L, Loibl S, Untch M, Hellström M, Johansson H, Anderson H, Malmström P, Gnant M, Greil R, Möbus V, Bergh J; Swedish Breast Cancer Group (SweBCG), the German Breast Group (GBG), and the Austrian Breast & Colorectal Cancer Study Group (ABCSG): Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. JAMA 2016, 316(18):1888-1896. (IF 37.684)

Loibl S, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Wiebringhaus H, Kümmel S, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Costa SD, Gerber B, Engels K, Nekljudova V, von Minckwitz G, Untch M; investigators of the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) study groups: Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. Ann Oncol. [Epub ahead of print] (IF 9.269)

Laakmann E, Witzel I, Scriba V, Grzyska U, Zu Eulenburg C, Burchardi N, Hesse T, Würschmidt F, Fehm T, Möbus V, von Minckwitz G, Loibl S, Park-Simon TW, Mueller V: Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry. Int J Mol Sci. 2016, 17(10). pii: E1615. 

Darb-Esfahani S, Denkert C, Stenzinger A, Salat C, Sinn B, Schem C, Endris V, Klare P, Schmitt W, Blohmer JU, Weichert W, Möbs M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Loi S, Untch M, von Minckwitz G, Nekljudova V, Loibl S: Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget. 2016, [Epub ahead of print]. 

Furlanetto J, Eiermann W, Marmé F, Reimer T, Reinisch M, Schmatloch S, Stickeler E, Thomssen C, Untch M, Denkert C, von Minckwitz G, Lederer B, Nekljudova V, Weber K, Loibl S, Möbus V: Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study. Ann Oncol. 2016 Aug 8. pii: mdw315. [Epub ahead of print] 

Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, Floris G, Fox SB, Gao D, Ingold Heppner B, Kim SR, Kos Z, Kreipe HH, Lakhani SR, Penault-Llorca F, Pruneri G, Radosevic-Robin N, Rimm DL, Schnitt SJ, Sinn BV, Sinn P, Sirtaine N, O'Toole SA, Viale G, Van de Vijver K, de Wind R, von Minckwitz G, Klauschen F, Untch M, Fasching PA, Reimer T, Willard-Gallo K, Michiels S, Loi S, Salgado R: Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol. 2016 Jul 1. doi: 10.1038/modpathol. 2016.109. [Epub ahead of print]

von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm DM, Hilfrich J, Costa SD, Dubsky P, Blohmer JU, Denkert C, Hanusch C, Jackisch C, Kümmel S, Fasching PA, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S; German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators: Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). Eur J Cancer. 2016 Jun 17;64:12-21. 

Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, Jiang J, Bartlett CH, Koehler M, Dowsett M, Bliss JM, Johnston SR, Turner NC: Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol. 2016, 34(25):2961-8. 

 

Harbeck N, Iyer S, Turner N, Cristofanilli M, Ro J, André F, Loi S, Verma S, Iwata H, Bhattacharyya H, Puyana Theall K, Bartlett CH, Loibl S: Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016, 27(6):1047-54. (IF 6.578)

Ingold Heppner B, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmitt WD, Eidtmann H, Fasching PA, Tesch H, Solbach C, Rezai M, Zahm DM, Holms F, Glados M, Krabisch P, Heck E, Ober A, Lorenz P, Diebold K, Habeck JO, Loibl S: Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant treated HER2-positive breast cancer. Clin Cancer Res. 2016 May 17. pii: clincanres.2338.2015. [Epub ahead of print] (IF 8.193)

Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga J: PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer - pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol. 2016 May 13. pii: mdw197. [Epub ahead of print] (IF 6.578)

Berns K, Sonnenblick A, Gennissen A, Brohée S, Hijmans ME, Evers B, Fumagalli D, Desmedt C, Loibl S, Denkert C, Neven P, Guo W, Zhang F, Knijnenburg TA, Bosse T, van der Heijden MS, Hindriksen S, Nijkamp W, Wessels LF, Joensuu H, Mills GB, Beijersbergen RL, Sotiriou C, Bernards R: Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance. Clin Cancer Res. 2016 May 12. pii: clincanres.2996.2015. [Epub ahead of print] (IF 8.193)

Budczies J, Pfarr N, Stenzinger A, Treue D, Endris V, Ismaeel F, Bangemann N, Blohmer JU, Dietel M, Loibl S, Klauschen F, Weichert W, Denkert C: Ioncopy: A novel method for calling copy number alterations in amplicon sequencing data including significance assessment. Oncotarget. 2016 (IF 6.63)

Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Darb-Esfahani S, Schmitt WD, Dan Costa S, Gerber B, Engels K, Nekljudova V, Loibl S, von Minckwitz G; German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigators: Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 2016 (IF 25.177)

Loibl S, Darb-Esfahani S, Huober J, Klimowicz A, Furlanetto J, Lederer B, Hartmann A, Eidtmann H, Pfitzner BM, Fasching PA, Tiemann K, Jackisch C, Mehta K, von Minckwitz G, Untch M, Denkert C: PTEN EXPRESSION AND p4EBP1 IMMUNOREACTIVE SCORE AS PREDICTOR FOR pCR IN HER2 POSITIVE BREAST CANCER . Clin Cancer Res. 2016 (IF 8.193)

Marmé F, Lederer B, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kümmel S, Loibl S, Paepke S, Untch M, von Minckwitz G, Schneeweiss A: Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer. 2016, 53:65-74. (IF 4.819)

Mitglieder der German Breast Group präsentierten im Jahr 2016 folgende Beiträge auf internationalen Kongressen:

Poster presented at SABCS 2016

SABCS 2016 San Antonio

Denkert C, von Minckwitz G, Darb-Esfahani S, Ingold Heppner B, Klauschen F, Furlanetto J, Pfitzner B, Huober J, Schmitt W, Blohmer J-U, Kümmel S, Engels K, Lederer B, Schneeweiss A, Hartmann A, Jakisch C, Untch M, Hanusch C, Weber K, Loibl S: Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 3771 patients. Oral presentation S1-09, SABCS 2016

Bidard F-C, Michiels S, Mueller V, Riethdorf S, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothe F, Smerage J, Muinelo L, Stebbing J, Viens P, Magbanua M, Hall CS, Engebråtenm O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran F-A, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf D, Bowman Bauldry J, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Ruud R, Tokiniwa H, Llombart-Cussac A, D'Hollander K, Cottu P, Park JW, Loibl S, Pierga J-Y, Pantel K: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy. Oral presentation S3-01, SABCS 2016

von Minckwitz G, Timms K, Untch M, Elkin EP, Hahnen E, Fasching PA, Schneeweiss A, Salat CT, Rezai M, Blohmer J-U, Zahm D-M, Jackisch C, Gerber B, Klare P, Kümmel S, Paepke S, Schmutzler R, Chau S, Reid J, Hartman A-R, Nekljudova V, Weber KE, Loibl S: Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Poster P1-09-02, SABCS 2016

van Mackelenberg M, Denkert C, Nekljudova V, Karn T, Schem C, Marme F, Stickeler E, Jackisch C, Hanusch C, Huober J, Fasching P, Blohmer J-U, Kümmel S, Müller V, Schneeweiss A, Untch M, von Minckwitz G, Weber K, Loibl S: Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Poster P1-09-11, SABCS 2016

van Mackelenbergh M, Loibl S, Jackisch C, Lück H-J, Schneeweiss A, Tesch H, Harbeck N, Schmatloch S, Fehm T, Huober J, Müller V, Bauerfeind I, Untch M, von Minckwitz G, Nekljudova V, Möbus V: Efficacy and safety of darbepoetin alfa or epoetin beta in 2994 high risk early breast cancer patients participating in the German adjuvant intergroup node-positive study (GAIN). Poster P2-11-04, SABCS 2016

Loibl S, Pfarr N, Weber K, Neunhöffer T, Villegas S, Stenzinger A, Furlanetto J, Aktas B, Budczies J, Marmé F, Kahmann L, Denkert C, Weichert W: Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls. Poster P2-03-09, SABCS 2016

Liedtke C, Kolberg H-C, Kerschke L, Goerlich D, Bauerfeind I, Fehm T, Fleige B, Hauschild M, Helms G, Lebeau A, Schmatloch S, Schrenk P, Schwentner L, Staebler A, von Minckwitz G, Loibl S, Untch M, Kuehn T: Development and validation of a nomogram predicting pathological axillary status (ypN0 vs. ypN+) in a subgroup of patients converting from cN+ to ycN0 through neoadjuvant therapy (NAT) - A transSENTINA substudy. Poster P3-13-06, SABCS 2016

Loibl S, Jackisch J, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kuemmel S, Luebbe K, Warm M, Just M, Hanusch C, Hackmann J, Blohmer J-U, Clemens M, Engels K, Nekljudova V, von Minckwitz G, Untch M: Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial. Poster P4-21-06, 2016

Furlanetto J, von Minckwitz G, Jackisch C, Schneeweiss A, Aktas B, Denkert C, Wiebringhaus H, Kuemmel S, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer J-U, Clemens M, Costa SD, Gerber B, Nekljudova V, Untch M, Loibl S: Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 69). Poster P5-16-03, SABCS 2016

ESMO 2016 Copenhagen

S. Loibl, A. Schneeweiss, N. Burchardi, J.-U. Blohmer, C. Hanusch, S. Costa, J. Huober, C. Jackisch, G. von Minckwitz, S. Kümmel, S. Paepke, C. Denkart, M. Untch: A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4673 (durvalumab) to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (GeparNuevo), ESMO 2016, 221TiP

S. Loibl, A. Demichele, N. Turner, M. Cristofanilli, S. Loi, S. Verma, H. Bhattacharyya, Z. Ke, C. Giorgetti, C. Bartlett, S. Iyer, M. Colleoni, N. Masuda, S.-A. Im, N. Harbeck: Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR + , HER2- metastatic breast cancer, ESMO 2016, 260P 

J. Bischoff, J. Barinoff, C. Mundhenke, D. Bauerschlag, S. Costa, D. Herr, K. Lübe, F. Marmé, N. Maass, G. von Minckwitz, E.-M. Grischke, V. Müller, M. Schmidt, B. Gerber, S. Kümmel, C. Schumacher, P. Krabisch, M. Thill, V. Nekljudova, S. Loibl: A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita, ESMO 2016, 273P 

F. André, B. Kaufman, D. Juric, E. Ciruelos, H. Iwata, I. Mayer, P. Conte, H.S. Rugo, S. Loibl, G. Rubovszky, H. Tesch, K. Inoue, Y.-S. Lu, L. Ryvo, A.-S. Longin, D. Mills, C. Wilke, C. Germa, M. Campone: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1), ESMO 2016, 311TiP 

G. Curigliano, S. Loibl, V. Müller, X. Pivot, A. Wardley, D. Cameron: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC), ESMO 2016, 312TiP

ASCO 2016 Chicago

Von Minckwitz G, Steffen J, Costa SD, Janni W, Thill M, Müller V, Neunhoeffer T, Lenhard HG, Feisel G, Schrader I, Kullmer U.E, Wittenberg M, Nekljudova V, Loibl S, German Breast Group: Quality of patient-reported outcome for long-term survival of early breast cancer trials. J Clin Oncol 34, 2016 (suppl; abstr e18121), ASCO 2016 Chicago

Kümmel S, von Minckwitz G, Nekljudova V, Costa SC, Denkert C, Hanusch C, Huober J, Jackisch C, Paepke S, Blohmer JU, Untch M, Schneeweiss A, Loibl S, German Breast Group: Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX). J Clin Oncol 34, 2016 (suppl; abstr TPS635), ASCO 2016 Chicago

Andre F, Campone M, Ciruelos EM, Iwata H, Loibl S, Rugo H, Wilke C, Mills D, Chol M, Longin A.S, Juric D: SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy. J Clin Oncol 34, 2016 (suppl; abstr TPS618), ASCO 2016 Chicago

Denkert D, Weber K, Krappmann K, Huober J, Marmé F, Schem C, Engels K, Pfitzner B.M, Kummel S, Furlanetto J, Hartmann A, Darb-Esfahani S, Mueller F, Staebler A, Mehta K, von Minckwitz G, Kronenwett R, Loibl S: Risk assessment after neoadjuvant chemotherapy in luminal breast cancer: A prospectively planned validation of gene expression based and clinical prognostic scores in 428 residual tumor samples from two neoadjuvant clinical trials. J Clin Oncol 34, 2016 (suppl; abstr 522), ASCO 2016 Chicago

Bergh J, Foukakis T, von Minckwitz G, Bengtsson N.O, Wallberg B, Fornander T, Mlineritsch B, Schmatloch S, Singer C. F, Steger G.G, Karlsson E, Carlsson L, Loibl S, Untch M, Hellstrom M, Johansson H, Malmstrom P, Gnant M, Greil R, Moebus V: PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy. J Clin Oncol 34, 2016 (suppl; abstr 1002), ASCO 2016 Chicago

Fasching P.A, Blohmer J.U, Burchardi N, Costa S.D, ,Denkert C, Hanusch C, Huober J.B, von Minckwitz G, Paepke S, Schneeweiss A, Kümmel S, Untch M, Loibl S, Jackisch C: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA. J Clin Oncol 34, 2016 (suppl; abstr TPS1096), ASCO 2016 Chicago

Schwentner L, Helms G, Nekljudova V, Ataseven B, Bauerfeind I, Ditsch N, Fehm T, Fleige B, Hauschild M, Heil J, Kümmel S, Lebeau A, Liedtke C, Loibl S, Schmatloch S, Schrenk P, Staebler A, Untch M, von Minckwitz G, Kühn T; Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy: Results from the prospective multi-center SENTINA trial. J Clin Oncol 34, 2016 (suppl; abstr 1054), ASCO 2016 Chicago

Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Eulenburg C, Schem C, Fasching P. A, Karn T, Fehm T, Kühn T, Overkamp F, Rack B, Denkert C, Untch M, Pantel K, Bokemeyer C, Loibl S, von Minckwitz, Loges S: Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial. J Clin Oncol 34, 2016 (suppl; abstr 11505), ASCO 2016 Chicago

Fontanella C, Lederer B, Del Mastro L, Denkert C, De Placido S, Hanusch C, Cognetti F, Huober J, De Laurentiis M, Jackisch C, Bisagni G, Kummel S, Garrone O, Schneeweiss A, Montemurro F, Untch M, Bighin C, von Minckwitz G, Loibl S,Puglisi F; Development and validation of a new prognostic score on 4,646 patients with luminal-like breast cancer (BC) enrolled in 7 randomized prospective trials. J Clin Oncol 34, 2016 (suppl; abstr 529), ASCO 2016 Chicago

Loibl S, Turner N. C, Ro J, Cristofanilli M, Iwata H, Im S. A, Masuda N, Loi S, Andre F, Harbeck N, Verma S, Folkerd E, Theall K.P, Zhang K, Huang Bartlett C, Dowsett N: Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy – results from Paloma-3. J Clin Oncol 34, 2016 (suppl; abstr 524), ASCO 2016 Chicago

Turner N. C, Jiang Y, O'Leary B, Hrebien S, Cristofanilli M, Andre F, Loibl S, English P. A, Zhang K, Randolph S, Huang Bartlett C, Koehler M, Loi S: ; Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA). J Clin Oncol 34, 2016 (suppl; abstr 512), ASCO 2016 Chicago

Valentina Nekljudova, Sibylle Loibl, Gunter Von Minckwitz, Stefan Gluck, Richard Crane, Huiling Li, Xiaolong Luo: A model for trial level prediction of long term outcome based on pathological complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC). J Clin Oncol 34, 2016 (suppl; abstr 1031) 

Volkmar Mueller, Sibylle Loibl, Elena Laakmann, Doris Augustin, Felix Flock, Hans Hermann Dohmen, Strittmatter Hans-Joachim, Matthias Frank, Tobias Hesse, Atanas Ignatov, Thorsten Kuehn, Tjoung-Won Park-Simon, Marcus Schmidt, Florian Wuerschmidt, Tanja N. Fehm, Volker Moebus, Gunter Von Minckwitz, Nicole Burchardi, Isabell Witzel: Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): Treatment patterns and clinical outcome of more than 1000 patients with brain metastases from breast cancer. J Clin Oncol 34, 2016 (suppl; abstr 2070)

 

AACR 2016 New Orleans

Loibl S, Budczies J, Weichert W, Furlanetto J, Stenzinger A, Pfarr N, von Minckwitz G, Jackisch C, Schneeweiss A, Fasching P, Schmatloch S, Aktas B, Nekljudova V, Weber K, Untch U, Denkert C: Prediction of therapy resistance by targeted massive-parallel sequencing in primary HER2-positive breast cancer. Abstract Number: 5010, Poster Session, AACR 2016 New Orleans

EBCC 2016 Amsterdam


S. Paepke, J. Huober, K. Sherko, H. Eidtmann, M. Untch, S. Dan Costa, J.U. Blohmer, W. Eiermann, B. Gerber, C. Hanusch, J. Hilfrich, C. Jackisch, A. Schneeweiss, C. Denkert, K. Engels , P. Klare, P. Fasching, N. Burchardi, S. Loibl, G. von Minckwitz: Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE). European Journal of Cancer 57, suppl. 2 (2016) S19–S153, Abstract number: 350, EBCC 2016 Amsterdam

DKK 2016 Berlin


B. Ingold Heppner, M. Untch, C. Denkert, B. M. Pfitzner, B. Lederer, W. Schmidt, H. Eidtmann, P. Fasching, H. Tesch, C. Solbach, M. Rezai, D.- M. Zahm, F. Holms, M. Glados, P. Krabisch, E. Heck, A. Ober, P. Lorenz, K. Diebold, J. Habeck, S. Loibl: Tumor-infiltrating lymphocytes and response prediction to neoadjuvant chemotherapy in HER2-positive breast cancer. Oncol Res Treat 2016;39(suppl 1):1–175, Abstract Nr. 512, Seite 5, DKK 2016 Berlin

E. Laakmann, I. Witzel, T. Fehm, T. Hesse, G. von Minckwitz, V. Möbus, T.-W. Park-Simon, T. Neunhöffer, M. Schmidt, S. Loibl, V. Müller: Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): The introduction of the multicenter register and analysis of patient data. Oncol Res Treat 2016;39(suppl 1):1–175, Abstract Nr. 236, Seite 50, DKK 2016 Berlin

B. Pfitzner, B. Lederer, J. Lindner, C. Solbach, K. Engels, M. Rezai, K. Dohnal, H. Tesch, M.- L. Hansmann, C. Salat, M. Beer, A. Schneeweiss, P. Sinn, G. von Minckwitz, C. Denkert, S. Loibl: HER2 testing in neoadjuvant breast cancer trials – improved concordance of HER2 status in different pathology laboratories. Oncol Res Treat 2016;39(suppl 1):1–175, Abstract Nr. 496, Seite 56, DKK 2016 Berlin

V. Möbus, H.- J. Lück, H. Forstbauer, G. Wachsmann, A. Ober, A. Schneeweiss, B. Christensen, E. von Abel, E.- M. Grischke, H.-G. Höffkes, P. Klare, Y.- D: GAIN2: Adjuvant phase III trial comparing an intensified dose-dense (idd) adjuvant therapy with EnPC compared to a dose-dense (dd), dose-adapted therapy with dtEC-dtD in patients with primary high risk breast cancer: Results of the second safety interim analysis. Oncol Res Treat 2016;39(suppl 1):1–175, Abstract Nr. 560, Seite 57, DKK 2016 Berlin

M. Untch, G. von Minckwitz, C. Jackisch, A. Schneeweiss, B. Conrad , B. Aktas, C. Denkert, H. Eidtmann, H. Wiebringhaus, S. Kümmel, J. Hilfrich, M. Warm, S. Paepke, M. Just, C. Hanusch, J. Hackmann, J. Uwe Blohmer, M. Clemens, S. Dan Costa, B. Gerber, V. Nekljudova, S. Loibl: nab-Paclitaxel at a dose of 125 mg/m² weekly is more efficacious but less toxic than at 150 mg/m². Results from the neoadjuvant randomized GeparSepto study (GBG 69). Oncol Res Treat 2016;39(suppl 1):1–175, Abstract Nr. 561, Seite 58, DKK 2016 Berlin

J. Furlanetto, W. Eiermann, F. Marmé, T. Reimer, M. Reinisch, S. Schmatloch, E. Stickeler, C. Thomssen, M. Untch, C. Denkert, G. von Minckwitz, V. Nekljudova, V. Möbus, S. Loibl: Higher Rate of Severe Toxicities in Obese Patients Receiving dose-dense (dd) Chemotherapy according to Unadjusted Body Mass Index – Results of the Prospectively Randomized GAIN study. Oncol Res Treat 2016;39(suppl 1):1–175, Abstract Nr. 562, Seite 58, DKK 2016 Berlin

J. Budczies, N. Pfarr, A. Stenzinger, D. Treue, V. Endris, F. Ismaeel, N. Bangemann, J.- U. Blohmer, M. Dietel, S. Loibl, W. Weichert, C. Denkert: Ioncopy: A novel method for calling copy number alterationsin amplicon sequencing data including significance assessment. Oncol Res Treat 2016;39(suppl 1):1–175, Abstract Nr. 460, Seite 123, DKK 2016 Berlin

Mitglieder der German Breast Group veröffentlichten im Jahr 2015 folgende Originalarbeiten:

Heil J, Kümmel S, Schaefgen B, Paepke S, Thomssen C, Rauch G, Ataseven B, Große R, Dreesmann V, Kühn T, Loibl S, Blohmer JU, von Minckwitz G: Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. Br J Cancer. 2015 113(11):1565-70. (IF 4.84)

Loibl S, Schmidt A, Gentilini O, Kaufman B, Kuhl C, Denkert C, von Minckwitz G, Parokonnaya A, Stensheim H, Thomssen C, van Calsteren K, Poortmans P, Berveiller P, Markert U, Amant F: Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA Oncol. 2015 1(8):1145-53. (IF 35.29)

Sonnenblick A, Brohée S, Fumagalli D, Rothé F, Vincent D, Ignatiadis M, Desmedt C, Salgado R, Sirtaine N, Loi S, Neven P, Loibl S, Denkert C, Joensuu H, Piccart M, Sotiriou C: Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. Oncotarget. 2015 6(30):30306-16. (IF 6.63)

Klauschen F, Wienert S, Schmitt WD, Loibl S, Gerber B, Blohmer JU, Huober J, Rüdiger T, Erbstößer E, Mehta K, Lederer B, Dietel M, Denkert C, von Minckwitz G: Standardized Ki67 Diagnostics Using Automated Scoring-Clinical Validation in the GeparTrio Breast Cancer Study. Clin Cancer Res. 2015, 15;21(16):3651-7. (IF 8.193)

Sonnenblick A, Brohée S, Fumagalli D, Vincent D, Venet D, Ignatiadis M, Salgado R, Van den Eynden G, Rothé F, Desmedt C, Neven P, Loibl S, Denkert C, Joensuu H, Loi S, Sirtaine N, Kellokumpu-Lehtinen PL, Piccart M, Sotiriou C: Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. BMC Med. 2015, 3;13(1):177. (IF 7.25)

Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M: Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015, 373(3):209-19. (IF 51.658)

Loibl S: The Dual Role of Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Two Sides of the Same Coin? JAMA Oncol. 2015;1(4):455-6.

von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marmé F, Potenberg J, Stickeler E, Simon E, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S; German Breast Group Investigators: A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer. 2015 (IF 4.889)

Loibl S, Jackisch C, Lederer B, Untch M, Paepke S, Kümmel S, Schneeweiss A, Huober J, Hilfrich J, Hanusch C, Gerber B, Eidtmann H, Denkert C, Costa SD, Blohmer JU, Nekljudova V, Mehta K, von Minckwitz G: Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Res Treat. 2015; 152(2):377-87. (IF 4.198)

Hein A, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer JU, Schwedler K, Kittel K, Fehm T, Kunz G, Beckmann MW, Ekici AB, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilboum RM, Loibl S, Fasching PA: Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase 3 GeparQuinto study. Int J Cancer. 2015 (IF 5.007)

Ataseven B, Lederer B, Blohmer JU, Denkert C, Gerber B, Heil J, Kühn T, Kümmel S, Rezai M, Loibl S, von Minckwitz G: Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. Ann Surg Oncol. 2015; 22(4):1118-27 (IF 6.578)

Hanusch CA, Schneeweiss A, Loibl S, Untch M, Paepke S, Kümmel S, Jackisch C, Huober J, Hilfrich J, Gerber B, Eidtmann H, Denkert C, Costa SD, Blohmer JU, Engels K, Burchardi N, von Minckwitz G: Dual blockade with AFatinib and trastuzumab as NEoadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy. Clin Cancer Res. 2015; 21(13):2924-31. (IF 8.193)

Martín M, Loibl S, von Minckwitz G, Morales S, Martinez N, Guerrero A, Anton A, Aktas B, Schoenegg W, Muñoz M, Garcia-Saenz JÁ, Gil M, Ramos M, Margeli M, Carrasco E, Liedtke C, Wachsmann G, Mehta K, De la Haba-Rodriguez JR: Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study. J Clin Oncol. 2015, 33(9):1045-52 (IF 17.879)

Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, Schem C, Fisch K, Darb-Esfahani S, Mehta K, Sotiriou C, Wienert S, Klare P, André F, Klauschen F, Blohmer JU, Krappmann K, Schmidt M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Untch M, Loibl S: Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers. J Clin Oncol. 2014, 33(9):983-91 (IF 17.879)

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259-71 (IF 6.578)

Fontanella C, Lederer B, Gade S, Vanoppen M, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Paepke S, Jackisch C, Mehta K, Nekljudova V, Untch M, Neven P, von Minckwitz G, Loibl S: Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat 2015, 150(1):127-39 (IF 4.198)

Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S, Szucs TD, Kronenwett R, Schwenkglenks M, Gnant M: Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. Pharmacoeconomics. 2015; 33(2):179-90 (IF 3.338)

Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; SOFT Investigators; International Breast Cancer Study Group: Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015; 372(5):436-46 (IF 51.658)

Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching PA, Pfitzner BM, Gerber B, Gade S, Darb-Esfahani S, Sinn BV, Huober J, Engels K, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, von Minckwitz G: Expression of Secreted Protein Acidic and Rich in Cysteine (SPARC) in Breast Cancer and Response to Neoadjuvant Chemotherapy. Ann Oncol. 2015; 26(1):95-100 (IF 6.578)

Lück HJ, Lübbe K, Reinisch M, Maass N, Feisel-Schwickardi G, Tomé O, Janni W, Aydogdu M, Neunhöffer T, Ober A, Aktas B, Park-Simon TW, Schumacher C, Höffkes HG, Illmer T, Wagner H, Mehta K, von Minckwitz G, Nekljudova V, Loibl S: Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer. Breast Cancer Res Treat 2015, 149(1):141-9 (IF 4.198)

Mitglieder der German Breast Group präsentierten im Jahr 2015 folgende Beiträge auf internationalen Kongressen:

14th St. Gallen International Breast Cancer Conference, 18 - 21 March 2015, Vienna, Austria 

Jackisch C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Thomssen C, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Fasching PA, Fehm T, Janni W, Lück HJ, Maass N, Scharl A, Untch M: 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel). 2015 10(3):211-9. 

DGHO, 9 - 13 October 2015, Basel, Switzerland

V. Möbus, HJ Lück, H. Forstbauer, G. Wachsmann, A. Ober, A. Schneeweiss, B. Christensen, E. von Abel, EM. Grischke, H.G. Höffkes, P. Klare, YD. Ko, S. Schmatloch, N. Burchardi, S. Loibl, G. von Minckwitz: GAIN2: Adjuvant phase III trial comparing an intensified dose-dense adjuvant therapy with EnPC compared to a dose-dense, dose-adapted therapy with dtEC-dtD in patients with primary high risk breast cancer: results of the second safety interim analysis. DGHO 2015, Oral presentation

European Cancer Congress, 25 - 29 September 2015, Vienna, Austria

Untch M, von Minckwitz G, Gerber B , Eidtmann H, Rezai M, Fasching PA,Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Loibl S: Neoadjuvant chemotherapy with trastuzumab or lapatinib: survival analysis of the HER2-positive cohort of the GeparQuinto study (GBG 44). ECCO 2015, Oral presentation

Senologiekongress, 25 - 27 June 2015, Leipzig

V. Möbus, HJ Lück, H. Forstbauer, G. Wachsmann, A. Ober, A. Schneeweiss, B. Christensen, E. von Abel, EM. Grischke, H.G. Höffkes, P. Klare, YD. Ko, S. Schmatloch, N. Burchardi, S. Loibl, G. von Minckwitz: GAIN2: Adjuvante Phase III Studie zum Vergleich einer intensivierten dosisdichten adjuvanten Therapie mit EnPC im Vergleich zu einer dosisdichten, adaptierten Therapie mit dtEC-dtD bei Patienten mit einem frühen Hochrisiko-Brustkrebs: Ergebnisse der zweiten Sicherheitsanalyse. Senologie 2015, Oral presentation

Loibl S, Furlanetto J, Barinoff J, Bauerschlag D, Herr D, Lübbe K, Maass N, Müller V, Mundhenke C, Schmidt M, Schwedler K, Thill K, Gkantiragas I, Burchardi N, von Minckwitz G: DESIREE - Eine multizentrische, randomisierte doppelblinde, Phase-II-Studie zum Vergleich der Verträglichkeit bei vorgeschalteter ansteigender Everolimus Dosierung bei Patienten mit metastasiertem Brustkrebs. Senologie 2015, Poster

Loibl S, Majewski I, Guarneri V, Nekljudova V, McCormick Holmes E, Bria E, Denkert C, Eidtmann H, Sotiriou C, Loi S, Andre F, Untch M, Conte PF, Piccart-Gebhart M, von Minckwitz G, Baselga J; German Breast Group, Neu-Isenburg, Germany: Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials. J Clin Oncol 33, 2015 (suppl; abstr 511)

Mueller V, Laakmann E, Fehm T, Moebus V, von Minckwitz G, Loibl S, Witzel I: Brain Metastases in Breast Cancer Network Germany (BMBC; GBG 79): Multicentric, retro- and prospective collection of patient data and biomaterial from patients with brain metastases. J Clin Oncol 33, 2015 (suppl; abstr TPS639)

Blank P, Loibl S, Linderholm BK, Caramuta S, Nekljudova V, Szucs TS, van Stiphout J, Ademi Z, von Minckwitz G, Schwenkglenks M: Cost-effectiveness analysis of VEGF-C: A novel predictive biomarker for response to bevacizumab in the neoadjuvant therapy of early breast cancer patients. J Clin Oncol 33, 2015 (suppl; abstr e12079)

Furlanetto J, von Minckwitz g, Lederer B, Möbus V, Lueck HJ, Hanusch C, Thomssen C, Untch M, Loibl S: Death during study treatment: An evaluation of events in 31 German clinical trials. J Clin Oncol 33, 2015 (suppl; abstr 1036)

Krug D, Lederer B, Debus J, Blohmer JU, Costa SD, Eidtmann H, Hanusch C, Hilfrich J, Huober JB, Jackisch C, Kümmel S, Paepke S, Schneeweiss A, Untch M, von Minckwitz G, Loibl S: Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials. J Clin Oncol 33, 2015 (suppl; abstr 1008)

Savas PS, Salgado R, Caramia F, Denkert C, Loibl S, Sotiriou C, Andre F, Speed TP, Loi S: Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC). J Clin Oncol 33, 2015 (suppl; abstr 613)

Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Bartlett SH, Zhang, Giorgetti C, Randolph S, Koehler M, Cristofanilli M: PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. J Clin Oncol 33, 2015 (suppl; abstr LBA502)

Von Minckwitz G, Timms K, Untch M, Elkin EP, Fasching PA, Schneeweiss A, Salat C, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, Kümmel S, Eidtmann H, Paepke S, Reid JE, Nekljudova V, Hartman AR, Loibl S: Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto. J Clin Oncol 33, 2015 (suppl; abstr 1004)

Schneeweiss A, Moebus V, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Hanusch C, Hilfrich J, Huober JB, Jackisch C, Paepke S, Kümmel S, Tesch H, Untch M, Loibl S, von Minckwitz G: A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). J Clin Oncol 33, 2015 (suppl; abstr TPS1101)

IMPAKT, 7 - 9 May 2015, Brussels, Belgium

A. Sonnenblick , S. Brohée , R. Salgado , G. Van den Eynden , P. Neven , S. Loibl , C. Denkert , H. Joensuu, M. Piccart, C. Sotiriou: Constitutively activated STAT3 is predictive for trastuzumab resistance in primary HER2. IMPAKT 2015, Poster

V. Müller, E. Laakmann, T. Fehm, V. Möbus, G. von Minckwitz, J. Kaiser, S. Loibl, I. Witzel: Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): Multicentric, retrospective and prospective collection of patient data and biomaterial from breast cancer patients as platform for translational research. IMPAKT 2015, Poster

G. von Minckwitz, B. Pfitzner, V. Müller, P. Fasching, T. Karn, C. Schem, K. Schönfeld, T. Häder, S. Loibl, C. Denkert: Expression of CD138 / syndecan-1 in triple-negative breast cancer – correlative study of GeparSixto. IMPAKT 2015, Poster

S. Avril , G. von Minckwitz , K. Malinowsky , P. Fasching , T. Karn , A. Hartmann , M. Untch , C. Denkert, K.-F. Becker, S. Loibl: Phosphoproteomic assessment of HER2 signaling pathway in HER2 non-amplified patients of the GeparQuattro and GeparQuinto trials. IMPAKT 2015, Poster

P. Blank , S. Loibl , B. Linderholm , S. Caramuta , V. Nekljudova , T. Szucs , J. Van Stiphout , Z. Ademi, G. von Minckwitz, M. Schwenkglenks: Cost-effectiveness analysis of VEGF-A testing to predict response to bevacizumab (BEV) as a component of neo-adjuvant therapy of early HER-2 negative breast cancer. IMPAKT 2015, Poster

S. Darb-Esfahani, W. Weichert, C. Denkert, G. von Minckwitz, V. Nekljudova, J. Lindner, V. Endris, F. Khandan, S. Loibl: p53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – A translational subproject of the GeparSixto trial. IMPAKT 2015, Poster

B. Pfitzner, S. Loibl, J. Lindner, P. Sinn, B. Lederer, S. Braun, K. Schmid, C. Denkert, G. von Minckwitz: Concordance of local and central HER2 status in 1597 patients participating in German neoadjuvant breast cancer studies. IMPAKT 2015, Poster

Poster presented at SABCS 2015

Mitglieder der German Breast Group veröffentlichten im Jahr 2014 folgende Originalarbeiten:

Klauschen F, Wienert S, Schmitt W, Loibl S, Gerber B, Blohmer JU, Huober J, Ruediger T, Erbstoesser E, Mehta K, Lederer B, Dietel M, Denkert C, von Minckwitz G: Standardized Ki67 diagnostics using automated scoring - clinical validation in the GeparTrio breast cancer study. Clin Cancer Res. 2014, [Epub ahead of print] (IF 8.193)

von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Gerber B; for the GBG/AGO-B study groups: Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto). Ann Oncol. 2014;25(12):2363-72 (IF 6.578)

Kriegsmann M, Endris V, Wolf T, Pfarr N, Stenzinger A, Loibl S, Denkert C, Schneeweiss A, Budczies J, Sinn P, Weichert W: Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget. 2014;5(20):9952-65 (IF 6.63)

Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, Sinn P, Khandan F, Eidtmann H, Dohnal K, Heinrichs C, Huober J, Pfitzner B, Fasching PA, Andre F, Lindner JL, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Denkert C: PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer. J Clin Oncol. 2014;32(29):3212-20. (IF 17.879)

Lönnstedt IM, Caramia F, Li J, Fumagalli D, Salgado R, Rowan A, Salm M, Kanu N, Savas P, Horswell S, Gade S, Loibl S, Neven P, Sotiriou C, Swanton C, Loi S, Speed TP: Deciphering clonality in aneuploid tumors using SNP array and sequencing data. Genome Biol. 2014;15(9):470 (IF 10.5)

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014; 25(8):1544-50 (IF 6.578)

Gerber B, von Minckwitz G, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Solbach C, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Nekljudova V, Loibl S, Untch M: Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44). Ann Surg Oncol 2014; 21(8):2517-24 (IF 3.943)

Müller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, Schwedler K, Lübbe K, Schem C, Fasching PA, Mau C, Pantel K, Schwarzenbach H: Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat 2014; 147(1):61-8 (IF 4.198)

Darb-Esfahani S, von Minckwitz G, Denkert C, Ataseven B, Högel B, Mehta K, Kaltenecker G, Rüdiger T, Pfitzner B, Kittel K, Fiedler B, Baumann K, Moll R, Dietel M, Eidtmann H, Thomssen C, Loibl S: Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. BMC Cancer. 2014; 14(1):546 (IF 3.319)

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384(9938):164-72 (IF 39.207)

Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014; 371(2):107-18. (IF 51.658)

Loibl S, Rokitta D, Conrad B, Harbeck N, Wüllner M, Warm M, Schwedler K, Gerber B, Schrader I, Eidtmann H, Mehta K, Fuhr U, von Minckwitz G: Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA. Breast Care (Basel). 2014;9(3):169-74. (IF 0.911)

Partridge AH, Pagani O, Abulkhair O, Aebi S, Amant F, Azim HA Jr, Costa A, Delaloge S, Freilich G, Gentilini OD, Harbeck N, Kelly CM, Loibl S, Meirow D, Peccatori F, Kaufmann B, Cardoso F: First international consensus guidelines for breast cancer in young women (BCY1). Breast 2014; 23(3):209-20 (IF 2.581)

Pfitzner BM, Branstetter D, Loibl S, Denkert C, Lederer B, Schmitt WD, Dombrowski F, Werner M, Rüdiger T, Dougall WC, von Minckwitz G: RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Res Treat 2014;145(2):307-15 (IF 4.198)

von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kümmel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15(7): 747-56 (IF 25.177)

Hilvo M, Gade S, Hyötyläinen T, Nekljudova V, Seppänen-Laakso T, Sysi-Aho M, Untch M, Huober J, von Minckwitz G, Denkert C, Orešič M, Loibl S: Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer 2014; 134(7):1725-33 (IF 5.007)

Loibl S, Volz C, Mau C, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Hanusch C, Jackisch C, Kümmel S, Huober J, Denkert C, Hilfrich J, Konecny GE, Fett W, Stickeler E, Harbeck N, Mehta KM, Nekljudova V, von Minckwitz G, Untch M: Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat 2014;144(1):153-62 (IF 4.198)

von Minckwitz G, Rezai M, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Blohmer JU, Costa SD, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Untch M: Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Ann Oncol 2014; 25(1):81-9 (IF 6.578)

Arsenic R, Lehmann A, Budczies J, Koch I, Prinzler J, Kleine-Tebbe A, Schewe C, Loibl S, Dietel M, Denkert C: Analysis of PIK3CA Mutations in Breast Cancer Subtypes. Diagn Mol Pathol 2014; 22(1):50-6 (IF 2.275)

Mitglieder der German Breast Group präsentierten im Jahr 2014 folgende Beiträge auf internationalen Kongressen:

San Antonio Breast Cancer Symposium (SABCS), December 9-13, 2014, San Antonio, USA

Loi S, Savas P, Lonnstedt I, Fumagalli D, Caramia F, Li J, Salgado R, Rowan A, Andre F, Denkert C, Neven P, Loibl S, Sotiriou C, Swanton C, Speed TP: Evaluation and clinical impact of intra-tumor heterogeneity (ITH) in primary HER2-overexpressing breast cancers (HER2+BC) treated with adjuvant trastuzumab and chemotherapy (CT). Poster discussion (PD3-1).

Loibl S, Darb-Esfahani S, Klimowicz A, von Minckwitz G, Lederer B, Huober J, Hartmann A, Eidtmann H, Pfitzner BM, Fasching PA, Tiemann K, Jackisch C, Mehta K, Untch M, Denkert C: PTEN and PIK3CA but not p4EBP1 are associated with low rates of pathological complete response (pCR) to trastuzumab based chemotherapy in primary HER2-overexpressing breast cancer. Poster discussion (PD5-7).

Witzel I, Laakmann E, Fehm T, Möbus V, vonMinckwitz G, Kaiser J, Loibl S, Müller V: Brain metastases in breast cancer network Germany (BMBC, GBG 79): Multicentric, retro- and prospective collection of patient data and biomaterial from breast cancer patients with brain metastases. Poster Session (OT2-5-01)

Untch M, Jackisch C, Schneeweiß A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer J-U, Clemens M, Costa SD, Gerber B, Nekljudova V, Loibl S, von Minckwitz G: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solventbased paclitaxel followed by anthracyline/ cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69. Oral presentation (S2-07).

von Minckwitz G, Reimer T, Potenberg J, Conrad B, Schürer U, Eidtmann H, Just M, Paepke S, Stickeler E, Heinrich G, Untch M, Moebus V, Thomssen C, Jackisch C, Huober J, Loibl S, Nekljudova V, Nitz U: The phase III ICE study: Adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Oral presentation (S3-04).

Loibl S, Brase JC, Gade S, Huober J, Krappmann K, Engels K, Fend F, Pfitzner BM, Hilfrich J, Thomssen C, Holzhausen HJ, Darb-Esfahani S, Schem C, Mehta K, Kronenwett R, von Minckwitz G, Denkert C: Predicting residual risk of recurrence after neoadjuvant chemotherapy- a retrospective analysis of EndoPredict® in the GeparTrio trial. Poster Session (P3-06-12).

Avril S, von Minckwitz G, Gündisch S, Gade S, Malinowsky K, Fasching PA, Karn T, Hartmann A, Untch M, Denkert C, Becker K-F, Loibl S: Assessment of phosphorylated HER2 protein as predictive biomarker to stratify anti-HER2 treatment in HER2 non-amplified patients - A translational study in the GeparQuattro and GeparQuinto trials. Poster Session (P3-06-36).

Gerber B, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer J-U, Hauschild M, Fehm T, Nekljudova V, von Minckwitz G: Neoadjuvant chemotherapy with or without bevacizumab or everolimus: Survival analysis of The HER2-negative cohort of the GEPARQUINTO study (GBG 44). Poster Session (P3-11-01).

Witzel I, Matschke J, Glatzel M, Milde-Langosch K, Laakmann E, Loibl S, Pfitzner BM, Denkert C, Müller V: SPARC expression in brain metastases of breast cancer patients. Poster Session (P6-16-09).

Kern P, von Minckwitz G, Pütter C, Flach A, Pavlidou S, Kimmig R, Rezai M: Stage-related risk categorization and influence of free margins on survival in triple negative early breast cancer - a population-based study of 2037 TNBC patients with adjuvant chemotherapy. Poster Session (P2-13-01).

Puglisi F, Cortes J, Vrdoljak E, Gligorov J, Marschner N, Zielinski C, de Laurentiis M, Brain E, Lévy C, Welt A, Kahan Z, Inbar M, de Ducla S, Freudensprung U, von Minckwitz G: Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Poster discussion (PD2-4).

Cortes J, Vrdoljak E, Puglisi F, Marschner N, Gligorov J, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, Veyret C, Fontana A, Oestergaard M, de Ducla S, Freudensprung U, von Minckwitz G: Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC). Poster Session (P3-06-08).

Halfter KML, Ditsch N, Kolberg H-C, Fischer H, Hauzenberger T, Edler von Koch F, Bauerfeind I, von Minckwitz G, Funke I, Crispin A, Mayer B: Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy - The SpheroNEO study. Poster Session (P3-06-13).

ESMO: European Cancer Congress, September 26-30, 2014, Madrid, Spain

Hanusch C, Schneeweiss A, Untch M, Paepke S, Kümmel S, Jackisch C,Huober J, Hilfrich J, Gerber B, Eidtmann H, Denkert C, Costa S, Blohmer JU, Loibl S, Burchardi N, von Minckwitz G: Dual blockade with Afatinib and Trastuzumab as neoadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy (DAFNE)-GBG70 – efficacy and safety analysis. Oral presentation, Abstract Nr. 255O

Noeding St., Forstbauer H., Wachsmann G., Ober A., Schneeweiss A., Christensen B., von Abel E., Grischke EM., Höffkes H.G., Klare P., Ko YD., Schmatloch S., Burchardi N., Loibl S., von Minckwitz G., Möbus V: GAIN2: Adjuvant phase III trial comparing an intensified dose-dense adjuvant therapy with EnPC compared to a dose-dense, dose-adapted therapy with dtEC dtDocetaxel in patients with primary breast cancer and a high risk of recurrence. Poster Discussion, Abstract Nr 264PD

Loibl S, De La Haba J. R., von Minckwitz G, Morales S, Crespo C, Antón A, Carrasco E, Aktas B, Mehta K, Martin Jimenez M: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the GEICAM/GBG LEA study. Safety analysis. Poster Discussion, Abstract Nr 323PD

Han S. N., Amant F, Sangalli C, Loibl S, Gheysens O, Lok C. A., Dahl K, Steffensen K, Halaska M. J., Peccatori F, Gentilini O: Sentinel lymph node biopsy for breast cancer treatment during pregnancy - on behalf of the International Network of Cancer, Infertility and Pregnancy (INCIP) and the German Breast Group (GBG). Poster Discussion, Abstract Nr 266PD_PR

Ataseven B, Blohmer J, Denkert C, Gerber B, Heil J, Kühn T, Kümmel S, Rezai M, Loibl S, von Minckwitz G: Impact of multifocal or multicentric disease on surgical, locoregional, and distant survival after neoadjuvant chemotherapy in 3562 breast cancer patients. Poster Discussion, Abstract Nr 321PD

Sinn B, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Belau A, Kronenwett R, Holzhausen H, Mehta K, Loibl S: Mucin-1 protein and mRNA expression in breast cancer patients treated with neoadjuvant chemotherapy. Best abstracts session, Abstract Nr 8O

ASCO: American Society of Clinical Oncology, May 30-June 3, 2014, Chicago, USA

Moebus V, von Minckwitz G, Jackisch C, Lueck HJ, Schneeweiss A, Tesch H, Elling D, Harbeck N, Conrad B, Fehm T, Huober J, Müller V, Bauerfeind I, Schmidt M, Loibl S, Nekljudova V, Untch M, Thomssen C: German Adjuvant Intergroup Node Positive (GAIN) study: A phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breast cancer—Final efficacy analysis. J Clin Oncol 32:5s, 2014 (suppl; abstr 1009), ASCO 2014

von Minckwitz G, Hahnen E, Fasching PA, Hauke J, Schneeweiss A, Salat C, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, Kummel S, Eidtmann H, Paepke S, Nekljudova V, Loibl S, Untch M, Schmutzler R, GBG and AGO-B Study Groups: Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. J Clin Oncol 32:5s, 2014 (suppl; abstr 1005), ASCO 2014

Fontanella C, Gade S, von Minckwitz G, Lederer B , Blohmer JU, Costa SC, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Paepke S, Jackisch C, Mehta K, Nekljudova V, Untch M, Loibl S; German Breast Group: Prognostic score for Luminal A-like breast cancer patients. J Clin Oncol 32:5s, 2014 (suppl; abstr 525), ASCO 2014

Denkert C, von Minckwitz G, Brase J, Darb-Esfahani S, Gade S, Kronenwett R, Salat C, Loi S, Schem C, Sotiriou C, Mehta K, Klare P, Fisch K, Blohmer JU, Tesch H, Kümmel S, Krappmann K, Dietel M, Untch M, Loibl S: Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy. Clin Oncol 32:5s, 2014 (suppl; abstr 510) ASCO 2014

Loibl S, Han S, Mayer K, MacMillan K, Gyapong S, Luebbe K, Weiss C, Schreiber K, Witzel I, Müller V, Schneeweiss A, Mundhenke C, Waldhoer C, Rezek D, Vogt N, Strobel S, Parokonnaya A, Nekljudova V, Amant F, von Minckwitz G: Neoadjuvant chemotherapy for patients with breast cancer during pregnancy (BCP). J Clin Oncol 32:5s, 2014 (suppl; abstr 1071), ASCO 2014

von Minckwitz G, O'Shaughnessy J, Winer E.P., Wolmark N, Geyer CE, Huober J, Loibl S, Sikov W.M., Untch M, McKee M, Giranda V, Rugo H: Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). J Clin Oncol 32:5s, 2014 (suppl; abstr TPS1149) ASCO 2014

Andre F, Daly F, Azim H, Agrapart V, Goulioti T, Pinto A, Saba C, Guitart M, Turner N, Pierrat JM, Loibl S, Chesnel T, Curigliano G, Loi S, Piccart-Gebhart M, Cortes J: FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS1134) ASCO 2014

Marinovich M, Houssami N, Macaskill P, von Minckwitz G, Blohmer JU, Irwig L: Accuracy of ultrasound during neoadjuvant therapy for breast cancer to predict pathologic response. J Clin Oncol 32:5s, 2014 (suppl; abstr 1089), ASCO 2014

Liedtke C, Goerlich D, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Staebler A, von Minckwitz G, Untch M, Kuehn T: Validation of a nomogram predicting nonsentinel lymphnode metastases among patients with breast cancer after neoadjuvant chemotherapy (NACT): A transSENTINA substudy. J Clin Oncol 32, 2014 (suppl; abstr e12022), ASCO 2014

Liedtke C, Goerlich D, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Staebler A, von Minckwitz G, Untch M, Kuehn T: Development of a novel nomogram predicting nonsentinel lymph node metastases among patients with breast cancer after neoadjuvant chemotherapy (NACT): A transSENTINA substudy. J Clin Oncol 32:5s, 2014 (suppl; abstr 1100), ASCO 2014

Mamounas E, Cortazar P, Zhang L, von Minckwitz G, Mehta K, Cameron D. A, Bonnefoi H.R., Gianni L, Valagussa P, Wolmark N, Loibl S, Bogaerts J, Swain S. M., Sridhara R, Costantino J. P., Rastogi P, Geyer C. E., Eidtmann H, Gerber B, Untch M: Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): Pooled-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC). J Clin Oncol 32, 2014 (suppl 26; abstr 61)

AACR: American Association for Cancer Research, April 5-8, 2014, San Diego, USA

Linderholm B.K., von Minckwitz G., Caramuta S., André F., Sotiriou C., Cerone M., Schwenkglenks M., Blank P., Denkert C., Gade S. and Loibl S. on behalf of the German Breast Group (GBG) neoadjuvant board and the RESPONSIFY consortium (EU FP7- HEALTH Collaborative project): Serum-Vascular Endothelial Growth Factors (sVEGF) A and C have a potential as predictive tests for neoadjuvant bevacizumab in primary breast cancer. Poster presentation, Abstract Nr. 896, AACR 2014

EBCC: European Breast Cancer Conference, March 19-21, 2014, Glasgow, Scotland

von Minckwitz G, Conrad B, Decker T, Reimer T, Hackmann J, Potenberg J, Bauer W, Jackisch C, Nekljudova V, Loibl S: Final results froma randomisedphase II study comparing epirubicinplus cyclophosphamide(EC)or CMF versus nabpaclitaxel plus capecitabine(PX)as adjuvant chemotherapy for elderly non-frail breast cancer patientswith an increased risk of relapse. Abstract Nr. 228, EBCC9-Programme book web-v2, Page 81, 2014

Loibl S, Blohmer J.U, Fasching P.A, Gerber B, Jackisch C, Kümmel S, Harbeck N, Mehta K.M, von Minckwitz G, Untch M: Response andprognosis after neoadjuvant chemotherapy in 1,051 patientswith infiltrating lobular carcinoma of the breast. Abstract Nr. 398, EBCC9-Programme book web-v2, Page 107, 2014

Fontanella C, Lederer B, Huober J, Gerber B, Mehta K.M, Nekljudova V, Gabe S, von Minckwitz G, Untch M, Loibl S: Effect of diabetesmellitus on early breast cancer patients receiving neoadjuvant therapy. Abstract Nr. 416, EBCC9-Programme book web-v2, Page 112, 2014

Fontanella C, Slaets L, Neven P, Loibl S, Vanoppen M, Bogaerts J, von Minckwitz G, Cameron D, Untch M, Bonnefoi H: Influence of bodymass index on long-termoutcome of breast cancer patients receiving neoadjuvant therapy - Combined results fromtheGBG(GermanBreast Group)and the EORTC cohorts. Abstract Nr. 417, EBCC9-Programme book web-v2, Page 112, 2014

DGGG / Senologie / DGHO
 

Laakmann E, Müller V, Fehm T, Möbus V, von Minckwitz G, Kaiser J, Loibl S, Witzel I: Brain Metastases in Breast Cancer Network Germany (BMBC): Eine multizentrische retrospektive und prospektive Datenbank und Biomaterialsammlung von Patientinnen mit Hirnmetastasen eines Mammakarzinoms. DGGG-Kongress in München, Geburtshilfe Frauenheilkd 2014; 74 - PO_Onko08_12

Liedtke C, Goerlich D, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Staebler A, von Minckwitz G, Untch M, Kühn T: Validierung eines Nomogramms zur Prädiktion von Non-Sentinellymphknoten-Metastasen bei Patientinnen mit primär-systemischer Therapie (PST) – eine transSENTINA Substudie. DGGG-Kongress München, Geburtshilfe Frauenheilkd 2014; 74 - PO_Onko07_07

Noeding St., Forstbauer H., Wachsmann G., Ober A., Schneeweiss A., Christensen B., von Abel E., Grischke EM., Höffkes H.G., Klare P., Ko YD., Schmatloch S., Burchardi N., Loibl S., von Minckwitz G., Möbus V: GAIN2: Adjuvante Phase III Studie zum Vergleich einer intensivierten dosisdichten adjuvanten Therapie mit EnPC im Vergleich zu einer dosisdichten, adaptierten Therapie mit dtEC-dtD bei Patienten mit einem frühen Hochrisiko-Brustkrebs. Senologie 2014, Senologie - Zeitschrift für Mammadiagnostik und -therapie 2014; 11 - A89

Laakmann E, Müller V, Fehm T, Möbus V, von Minckwitz G, Kaiser J, Loibl S, Witzel I: Brain Metastases in Breast Cancer Network Germany (BMBC): Eine multizentrische retrospektive und prospektive Datenbank und Biomaterialsammlung von Patientinnen mit Hirnmetastasen eines Mammakarzinoms. Senologie 2014, Senologie - Zeitschrift für Mammadiagnostik und -therapie 2014; 11 - A73

Liedtke C, Goerlich D, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Staebler A, von Minckwitz G, Untch M, Kühn T: Validierung eines Nomogramms zur Prädiktion von Non-Sentinellymphknoten-Metastasen bei Patientinnen mit primär-systemischer Therapie (PST) – eine transSENTINA Substudie. Senologie 2014, Senologie - Zeitschrift für Mammadiagnostik und -therapie 2014; 11 - A75

Noeding St., Forstbauer H., Wachsmann G., Ober A., Schneeweiss A., Christensen B., von Abel E., Grischke EM., Höffkes H.G., Klare P., Ko YD., Schmatloch S., Burchardi N., Loibl S., von Minckwitz G., Möbus V: GAIN2: Adjuvante Phase III Studie zum Vergleich einer intensivierten dosisdichten adjuvanten Therapie mit EnPC im Vergleich zu einer dosisdichten, adaptierten Therapie mit dtEC-dtD bei Patienten mit einem frühen Hochrisiko-Brustkrebs. DGHO Hamburg 2014, Vortrag Nr V373, S. 89

Mitglieder der German Breast Group veröffentlichten im Jahr 2013 folgende Originalarbeiten:

Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, Sinn BV, Ulmer HU, Kronenwett R, Just M, Kühn T, Diebold K, Untch M, Holms F, Blohmer JU, Habeck JO, Dietel M, Overkamp F, Krabisch P, von Minckwitz G, Denkert C: Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer - A Substudy of the Neoadjuvant GeparQuinto Trial. PLoS One. 8(12), 2013 (IF 3.73)

Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Nekljudova V, Untch M, von Minckwitz G; on behalf of the German Breast Group Investigators: Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol. 24(12):2978-84, 2013 (IF 6.425)

Hilvo M, Gade S, Hyötyläinen T, Nekljudova V, Seppänen-Laakso T, Sysi-Aho M, Untch M, Huober J, von Minckwitz G, Denkert C, Orešič M, Loibl S: Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer. 134(7):1725-33, 2013 (IF 6.198)

Maass N, Harbeck N, Mundhenke C, Lerchenmüller C, Barinoff J, Lück HJ, Ettl J, Aktas B, Kümmel S, Rösel S, Wagner S, Müller L, Bischoff J, Lübbe K, Schwedler K, Schmidt M, Bauerschlag D, Nekljudova V, von Minckwitz G, Loibl S; On behalf of the German Breast Group: Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. J Cancer Res Clin Oncol. 139(12):2047-56, 2013 (IF 2.912)

von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Kümmel S, Paepke S, Schneeweiss A, Untch M, Zahm DM, Mehta K, Loibl S: Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 31(29):3623-30, 2013 (IF 18.970)

von Minckwitz G, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel IJ, Elling D, Conrad B, Kreienberg R, Müller V, Lück HJ, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Loibl S: German Adjuvant Intergroup Node-Positive Study: A Phase III Trial to Compare Oral Ibandronate Versus Observation in Patients With High-Risk Early Breast Cancer. J Clin Oncol. 31(28):3531-9, 2013 (IF 18.970)

Denkert C, Loibl S, Müller BM, Eidtmann H, Schmitt WD, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Erbstößer E, Blohmer JU, Budczies J, Mehta KM, von Minckwitz G: Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol. 24(11):2786-93,2013 (IF 6,425)

Ruckhäberle E, Karn T, Denkert C, Loibl S, Ataseven B, Reimer T, Becker S, Holtrich U, Rody A, Darb-Esfahani S, Nekljudova V, von Minckwitz G: Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer. J Cancer Res Clin Oncol. 139(10):1681-9, 2013 (IF 2.912)

von Minckwitz G, Schmitt WD, Loibl S, Müller BM, Blohmer JU, Sinn BV, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Rüdiger T, Erbstoesser E, Fasching PA, Karn T, Müller V, Jackisch C, Denkert C: Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer. Clin Cancer Res. 19(16):4521-4531, 2013 (IF 7,837)

Lück HJ, Du Bois A, Loibl S, Schrader I, Huober J, Heilmann V, Beckmann M, Stähler A, Jackisch C, Hubalek M, Richter B, Stickeler E, Eidtmann H, Thomssen C, Untch M, Wollschläger K, Schuster T, von Minckwitz G: Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat. 139(3):779-87, 2013 (IF 4,431)

Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G, Belau A, Thommsen C, Holzhausen HJ, Grasshoff ST, Baumann K, Mehta K, Dietel M, Loibl S: Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann Oncol. 24(9):2316-24,0213 (IF 6,425)

Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Untch M, Witteveen PO, Schwedler K, Thomssen C, Van Calster B, Loibl S: Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study. J Clin Oncol. 31(20):2532-9, 2013 (IF 18.970)

Huober J, Fasching PA, Hanusch C, Rezai M, Eidtmann H, Kittel K, Hilfrich J, Schwedler K, Blohmer JU, Tesch H, Gerber B, Höß C, Kümmel S, Mau C, Jackisch C, Khandan F, Costa SD, Krabisch P, Loibl S, Nekljudova V, Untch M, Minckwitz GV: Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab - Results of the randomised GeparQuinto study (GBG 44). Eur J Cancer. 49(10):2284-93, 2013 (IF 5.536)

Denkert C, Huober J, Loibl S, Prinzler J, Kronenwett R, Darb-Esfahani S, Brase JC, Solbach C, Mehta K, Fasching PA, Sinn BV, Engels K, Reinisch M, Hansmann ML, Tesch H, von Minckwitz G, Untch M: HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res. 15(1):R11, 2013 (IF 5.245)

Denkert C, Loibl S, Kronenwett R, Budczies J, von Törne C, Nekljudova V, Darb-Esfahani S, Solbach C, Sinn BV, Petry C, Müller BM, Hilfrich J, Altmann G, Staebler A, Roth C, Ataseven B, Kirchner T, Dietel M, Untch M, von Minckwitz G: RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy. Ann Oncol. 24(3):632-9, 2013 (IF 6,425)

Mitglieder der German Breast Group präsentierten im Jahr 2013 folgende Beiträge auf internationalen Kongressen:

San Antonio Breast Cancer Conference

Loibl S, Denkert C, Schneeweis A, Paepke S, Lehmann A, Rezai M, Zahm D-M, Sinn P, Khandan F, Eidtmann H, Dohnal K, Huober J, Loi S, Pfitzner B, Fasching PA, Andre F, Lindner J, Sotiriou C, Guo S, Gade S, Nekljudova V, Untch M, von Minckwitz G: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer – Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies. (presentation)

von Minckwitz G, Rezai M, Eidtmann H, Tesch H, Huober J, Gerber B, Zahn DM, Costa S, Gnant M, Blohmer JU, Denkert C, Hanusch C, Jackisch C, Kümmel S, Fasching PA, Schneeweiss A, Paepke S, Untch M, Nekljudova V, Mehta K, Loibl S: NATAN slide presentation Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer – The phase III NATAN study (GBG 36/ABCSG XX). (presentation)

Denkert C, Loibl S, Salat C, Sinn BV, Schem C, Endris V, Klare P, Schmitt WD, Blohmer J-U, Weichert W, Tesch H, Darb-Esfahani S, Kümmel S, Sinn P, Stenzinger A, Jackisch C, Dietel M, Reimer T, Loi S, Mehta K, Gade S, Untch M, von Minckwitz G: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). (presentation)

Cuzick J, Sestak I, Forbes JF, Cawthorn S, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A, Knox J, Dowsett M, Saunders C: First results of the International breast cancer intervention study II (IBIS-II): A multicentre prevention trial of anastrozole versus placebo in postmenopausal women at increased risk of developing breast cancer. (presentation)

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Brown DN, Kellokumpu-Lehtinen P-L, Bono P, Kataja V, Desmedt C, Piccart-Gebhart MJ, Loibl S, Untch M, Denkert C, Smyth MJ, Joensuu H, Sotiriou C: 05. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). (presentation)

Fontanella C, von Minckwitz G, Mergler B, Neven P, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Gerber B, Vanoppen M, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Paepke S, Jackisch C, Keyur M, Nekljudova V, Untch M, Loibl S: Body mass index (BMI) and treatment outcome of breast cancer patients receiving neoadjuvant therapy (NACT). (poster discussion)

von Minckwitz G, Bear H, Bonnefoi H, Colleoni M, Gelmon K, Gnant M, Kim S-B, Loibl S, Makris A, Martin M, Nekljudova V, Rugo H, Saini KS, Toi M, Untch M, Werutsky G. German Breast Group: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13). (poster presentation)

von Minckwitz G, Kern P, Schneeweiss A, Gluz O, Harbeck N, Neumann M, Badiian M, Fries H, Rezai M: Features of neoadjuvant and adjuvant chemotherapy in breast cancer – A population-based study on 39404 patients. (poster presentation)

Geyer CE, Loibl S, Mamounas EP, Untch M, Wolmark N, Huang C-S, Mano M, Zheng M, Smitt M, von Minckwitz G: A phase 3, randomized, open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE). (poster presentation)

Loibl S, Mergler B, Eppel A, Solbach C, Lübbe KM, Eidtmann H, Rezai M, Hanusch C, Fehm T, Bartzke G, Burgmann D-M, Krabisch P, Untch M, Nekljudova V, von Minckwitz G: The choice of the indicator lesion impacts on the pCR rate – An analysis of 114 bilateral breast cancer patients treated within neoadjuvant trials. (poster presentation)

Loi S, Loibl S, Di Cosimo S, Nekljudova V, Flamen P, Saini KS, Michiels S, de la Pena L, Nanni S, Urban P, Piccart M, Von Minckwitz G, Baselga J: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer – NeoPHOEBE. (poster presentation)

ECCO / ESMO

Loibl S, De la Haba J, von Minckwitz F, Morales S, Crespo C, Antón A, Carrasco E, Aktas B, Mehta K, Martin M on behalf of GEICAM and GBG: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer - Final Analysis LEA study.

ASCO

von Minckwitz G, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P, Blohmer JU, Tesch H, Khandan F, Jud S, Jackisch C, Mehta K, Loibl S, Untch M, German Breast Group: A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). J Clin Oncol 31, 2013 (suppl; abstr 1004)

Loibl S, Denkert C, Loi S, Andre F, Mueller B, Schneeweiss A, Blohmer JU, Jackisch C, Sanxing G, Gade S, Fasching PA, Schem C, Sotiriou C, Untch M, von Minckwitz G, German Breast Group: PIK3CA mutations in primary HER2-positive and triple negative breast cancer. J Clin Oncol 31, 2013 (suppl; abstr 11061)

Lueck HJ, Luebbe K, Bischoff J, Maass N, Feisel G, Tome O, Janni W, Aydogdu M, Neuhoeffer T, Ober A, Aktas B, Park-Simon TW, Schumacher C, Hoeffkes HG, Illmer T, Wagner H, Mehta K, Nekljudova V, Loibl S, von Minckwitz G, German Breast Group: A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 31, 2013 (suppl; abstr 1082)

Jackisch C, Wiebringhaus F, Conrad B, Weigel M, Aktas B, Wagner H, Latos K, Kohls A, Bueckner U, Hauzenberger T, Bangemann N, Hackmann J, Clemens MR, Heinrich B, Tome O, Loibl S, Nekljudova V, von Minckwitz G, German Breast Group: A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto): GBG 69. J Clin Oncol 31, 2013 (suppl; abstr TPS1141)

Moebus V, Forstbauer H, Wachsmann G, Schneeweiss A, Ober A, von Abel E, Krabisch P, Hoeffkes HG, Kast K, Christensen B, Niedermeier M, Deryal M, Uleer C, Fauster I, Goehler T, Loibl S, Nekljudova V, von Minckwitz G, German Breast Group: Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2). J Clin Oncol 31, 2013 (suppl; abstr TPS1137)

Paepke S, Kümmel S, Blohmer JU, Costa SD, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober JB, Jackisch C, Schneeweiss A, Denkert C, Mehta K, Loibl S, von Minckwitz G, German Breast Group: Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal b/HER2 normal breast cancer (GENEVIEVE). J Clin Oncol 31, 2013 (suppl; abstr TPS1138)

Michiels S, Pugliano L, Grun D, Barinoff J, Cameron DA, Cobleigh MA, Di Leo A, Johnston SRD, Gasparini G, Kaufman B, Marty ME, Nekljudova V, Paluch-Shimon S, Penault-Llorca F, Slamon DJ, Vogel CL, von Minckwitz G, Buyse ME, Piccart-Gebhart MJ: Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis. J Clin Oncol 31, 2013 (suppl; abstr 610)

Liedtke C, Goerlich D, Van Zee KJ, Korndoerfer J, Bauerfeind I, Fehm TN, Fleige B, Helms G, Annette Lebeau, Mai M, Staebler A, von Minckwitz G, Untch M, Kühn T: Predicting nonsentinel lymph node metastases using established nomograms among patients with breast cancer after primary systemic therapy (PST): The transSENTINA substudy. J Clin Oncol 31, 2013 (suppl; abstr 1020)

St. Gallen Congress

Untch M, Loibl S, Jackisch C, Wiebringhaus H, Forstbauer H, Wachsmann G, Zofia Maczynska, Valentina Nekljudova, Gunter von Minckwitz, Volker Möbus: Safety of 150mg/m²nab-paclitaxel weekly either as weekly or as 300mg/m² biweekly regimen. Poster presentation (Poster # 249) at St. Gallen Congress 2013

AACR

von Minckwitz G, Mamouhdian-Dekordi C, Loibl S, Blohmer J-U, Costa S, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Paepke S, Mehta K, Untch M, Jackisch C: Response characteristics and overall survival of 781 patients with triple-negative breast cancer – a meta-analysis on 7 German neoadjuvant studies. Poster presentation (Poster # 1195) AACR in Washington, 2013

Loibl S, Denkert C, Loi S, Andre F, Schneeweiss A, Blohmer J, Jackisch C, Gade S, Fasching P, Schem C, Sotiriou C, Untch M, von Minckwitz G: PIK3CA mutations in primary HER2-positive and triple negative breast cancer. Poster presentation (Poster # 1220) at AACR in Washington, 2013

Mitglieder der German Breast Group veröffentlichten im Jahr 2012 folgende Originalarbeiten:

Loibl S, Han SN, von Minckwitz G, Bontenbal M, Ring A, Giermek J, Fehm T, Van Calsteren K, Linn SC, Schlehe B, Gziri MM, Westenend PJ, Müller V, Heyns L, Rack B, Van Calster B, Harbeck N, Lenhard M, Halaska MJ, Kaufmann M, Nekljudova V, Amant F: Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 13(9):887-96, 2012

Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, Ray-Coquard I, Sehouli J, Harter P, du Bois A; on behalf of the AGO and GINECO study group: The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 23(10):2605-2612, 2012

Witzel I, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Fasching PA, Mau C, Schem C, Rack B, Meinhold-Heerlein I, Liedtke C, Karn T, Huober J, Zu Eulenburg C, Issa-Nummer Y, Untch M, Müller V: Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab - a translational project in the neoadjuvant GeparQuinto trial. Br J Cancer. 107(6):956-60, 2012

Ditsch N, Vodermaier A, Hinke A, Burghardt S, Lenhard M, Löhrs B, Toth B, VON Koch F, Kahlert S, Bauerfeind I, Konecny GE, Loibl S, von Minckwitz G, Untch M: Dose-dense Intensified Sequential Versus Conventionally-dosed Anthracycline and Taxane-containing Neoadjuvant Therapy in Patients with Inflammatory Breast Cancer. Anticancer Res. 32(8):3539-45, 2012

Massey Skatulla L, Loibl S, Schauf B, Müller T: Pre-eclampsia following chemotherapy for breast cancer during pregnancy: case report and review of the literature. Arch Gynecol Obstet. 286(1):89-92, 2012

Loibl S, Han SN, Amant F: Being Pregnant and Diagnosed with Breast Cancer. Breast Care (Basel 7(3):204-209, 2012

Denkert C, Bucher E, Hilvo M, Salek R, Orešč M, Griffin J, Brockmöller S, Klauschen F, Loibl S, Barupal DK, Budczies J, Iljin K, Nekljudova V, Fiehn O: Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med. 4(4):37, 2012

von Minckwitz G, Untch M, Blohmer J-U, Costa S-D, Eidtmann H, Fasching P.A, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny G, Denkert C, Nekljudova V, Mehta K, Loibl S for the GBG and AGO-B study groups: Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 30(15):1796-804, 2012

Azim HA Jr, Metzger-Filho O, de Azambuja E, Loibl S, Focant F, Gresko E, Arfi M, Piccart-Gebhart M: Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res Treat. 133(1):387-91, 2012

Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, Reed M, Ciatto S, Voogd AC, Brain E, Cutuli B, Terret C, Gosney M, Aapro M, Audisio R: Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 13(4):e148-60, 2012

von Minckwitz G, Nekljudova V, Loibl S: What can be learned from trials running short of patients or events? J Clin Oncol. 30(9):901-3, 2012

von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups: Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 366(4):299-309, 2012

Chan A, Verma S, Loibl S, Crawford J, Choi MR, Dreiling L, Vandenberg T: Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Crit Rev Oncol Hematol. 81(2):136-50, 2012

Brockmöller SF, Bucher E, Müller BM, Budczies J, Hilvo M, Griffin JL, Orešič M, Kallioniemi O, Iljin K, Loibl S, Darb-Esfahani S, Sinn BV, Klauschen F, Prinzler J, Bangemann N, Ismaeel F, Fiehn O, Dietel M, Denkert C: Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer - link to patient survival, hormone receptor status and metabolic profiling. J Proteome Res. 11(2):850-60, 2012

Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G; for the German Breast Group (GBG); the Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group: Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 13(2):135-144, 2012

von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups: Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 366(4):299-309, 2012

Mitglieder der German Breast Group präsentierten im Jahr 2012 folgende Beiträge auf internationalen Kongressen:

SABCS

Martin M, Loibl S, von Minckwitz G, Morales S, Crespo C, Anton A, Guerrero A, Aktas B, Schoenegg W, Muñoz M, Garcia-Saenz JA, Gil M,Ramos M, Carrasco E, Liedtke C, Wachsmann G, Mehta K, De la Haba J R: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer - First efficacy results from the LEA study. Cancer Res 72 (24 Suppl.): 91s, 2012

Kuehn T, Bauerfeind IGP, Fehm T, Fleige B, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schrenk P, Staebler A, Untch M: Sentinel lymph node biopsy before or after neoadjuvant chemotherapy - final results from the prospective German, multiinstitutional SENTINA-trial. Cancer Res 72 (24 Suppl.): 95s, 2012

Loibl S, Jackisch C, Gade S, Untch M, Paepke S, Kuemmel S, Schneeweiss A, Jackisch C, Huober J, Hilfrich J, Hanusch C, Gerber B,Eidtmann H, Denkert C, Costa S-D, Blohmer J-U, Nekljudova V, Mehta K, von Minckwitz G: Neoadjuvant chemotherapy in the very young 35 years of age or younger. Cancer Res 72 (24 Suppl.): 96s, 2012

Denkert C. Blohmer JU, Müller BM, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Budczies J, Erbstößer E, Loibl S, von Minckwitz G: Ki67 levels in pretherapeutic core biopsies as predictive and prognostic parameters in the neoadjuvant GeparTrio trial. Cancer Res 72 (24 Suppl.): 102s, 2012

Klauschen F, Wienert S, Blohmer J-U, Mueller BM, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Erbstoesser E, Loibl S, Denkert C, von Minckwitz G: Automated computational Ki67 scoring in the GeparTrio breast cancer study cohort. Cancer Res 72 (24 Suppl.): 33s, 2012

von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Blohmer J-U, Costa S-D, Jackisch C, Paepke S, Schneeweiss A, Kuemmel S, Denkert C, Mehta K, Untch M: Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Res 72 (24 Suppl.): 15s, 2012

Untch M, Prinzler J, Fasching P, Müller BM, Gade S, Meinhold-Heerlein I, Huober J, Karn T, Liedtke C, Loibl S, Müller V, Rack B, Schem C, Darb-Esfahani S, von Minckwitz G, Denkert C: Expression of SPARC in human breast cancer and its predictive value in the GeparTrio neoadjuvant trial. Cancer Res 72 (24 Suppl.): 36s, 2012

Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring A, Giermek J, Fehm T, Wildiers H, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Lenhard M, Witteveen PO, Kaufmann M, Van Calster B, Loibl S: Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial. Cancer Res 72 (24 Suppl.): 71s, 2012

Hanusch C, Schneeweiss A, Untch M, Paepke S, Kuemmel S, Jackisch C, Huober J, Hilfrich J, Gerber B, Eidtmann H, Denkert C, Costa S-D, Blohmer J-U, Loibl S, Nekljudova V, von Minckwitz G: Dual blockade with Afatinib and Trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy (DAFNE)-GBG70. Cancer Res 72 (24 Suppl.): 18s, 2012

Linder M, von Minckwitz G, Kamischke A, Rudolwski C, Eggemann H, Nekljudova V, Loibl S: A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (GBG-54 MALE). Cancer Res 72 (24 Suppl.): 43s, 2012

Untch M, Jackisch C, Blohmer J-U, Costa S-D, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Kuemmel S, Schneeweiss A, Paepke S, Loibl S, Nekljudova V, von Minckwitz G: A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto) GBG 69. Cancer Res 72 (24 Suppl.): 67s, 2012

Thomssen C, Kantelhardt EJ, Meisner C, Vetter M, Schmidt M, Martin P-M, Veyret C, Augustin D, Hanf V, Paepke D, Meinerz W, Hoffmann G, Wiest W, Sweep FCGJ, Schmitt M, Jaenicke F, von Minckwitz G, Harbeck N: First planned efficacy analysis of the NNBC 3-Europe trial: Addition of docetaxel to anthracycline containing adjuvant chemotherapy in high risk node-negative breast cancer patients. Cancer Res 72 (24 Suppl.): 15s, 2012

ESMO

Ataseven B, Blohmer J.U, Denkert C BeGerber B, Heil J, Kühn T, Kümmel S, Rezai M, Loibl S, von Minckwitz G for the GBG and AGO-B Study Groups: Impact of multifocal or multicentric disease on surgical, locoregional, and distant survival after neoadjuvant chemotherapy in 3562 breast cancer patients. Annals of Oncology Volume 23 (Supplement 9), 117, 2012

Loibl S, De la Haba J, von Minckwitz G, Morales S, Crespo C, Antón A, Carrasco E, Aktas B, Mehta K, Martin M: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer - Safety Analysis LEA study. Annals of Oncology Volume 23 (Supplement 9), 118, 2012

ASCO

von Minckwitz G, Mueller B, Blohmer J.U, Kaufmann M, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Ruediger T, Erbstoesser E, Loibl S, Denkert C: Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial. J Clin Oncol 30, (suppl; abstr 1023), 2012

Huober J, Denkert C, Minckwitz G, Prinzler J, Kronenwett R, Darb-Esfahani S, Mehta K, Sinn B.V, Untch M, Loibl S: Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. J Clin Oncol 30, (suppl; abstr 523), 2012

Maass N, Harbeck N, Mundhenke C, Lerchenmuller C, Barinoff J, Lueck H.J, Ettl J, Aktas B, Kuemmel S, Roesel S, Wagner S, Müller L, Bischoff J, Luebbe K, Schwedler K, Schmidt M, Bauerschlag D, Nekljudova V, Loibl S, von Minckwitz G: Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: Results of the phase II RADAR study. J Clin Oncol 30, (suppl; abstr 556), 2012

Pirvulescu C, Loibl S, von Minckwitz G, Mau C, Blohmer J.U, Dan Costa S, Eidtmann H, Fasching P.A, Gerber B, Untch M: Response pattern in 844 patients with infiltrating lobular carcinoma (ILC) of the breast after neoadjuvant chemotherapy. J Clin Oncol 30, (suppl; abstr 541), 2012

Sinn B.V, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Belau A, Kronenwett R, Holzhausen H.J, Mehta K, Loibl S: Mucin-1 protein and mRNA expression in breast cancer: Predictive value for therapy response and survival after neoadjuvant chemotherapy. J Clin Oncol 30, (suppl; abstr 522), 2012

EBCC

Harbeck N, Maass N, Mundhenke C, Lerchenmüller C, Barinoff J, Etti J, Aktas B, Nekljudova V, von Minckwitz, Loibl S: Everolimus (Rad001) as Treatment in Breast Cancer Patients with Bone Metastases Only – First Results of the Multi-centre, Placebo-controlled, Randomized Discontinuation Phase II RADAR Study. European Journal of Cancer Vol. 48, Supplement 1, S43, 2012

Loibl S, von Minckwitz G, Kaufmann M: Adjuvant hormone therapy following primary therapy for endometrial cancer Preview. European Journal of Cancer Vol. 38, Supplement 6, 41-43, 2012

von Minckwitz G, Steffen J, Wiest W, Thomssen C, Augustin D, Conrad B, Wesenberg B, Wittenberg M, Loibl S: Patient Self-reported Outcome for Long-term Follow up of Early Breast Cancer Trials. European Journal of Cancer Vol. 48, Supplement 1, S52, 2012

Loibl S, Gerber B: Managing adverse effects of treatment – Fertility. European Journal of Cancer Vol. 48, Supplement 1, S101, 2012

Loibl S: Breast Cancer in the Young. European Journal of Cancer Vol. 48, Supplement 1, S45, 2012

Mitglieder der German Breast Group veröffentlichten im Jahr 2011 folgende Originalarbeiten:

Guo X, Loibl S, Untch M, Möbus V, Schwedler K, Fasching P.A. Barinoff J, Holms F, Thomssen C, Zahm D-M, Kreienberg R, Hauschild M, Eidtmann H, Tauchert S, Mehta K, von Minckwitz G, for the German Breast Group and AGO-B Study Group: Re-challenging taxanes in recurrent breast cancer in patients treated with (neo-) adjuvant taxane-based therapy. Breast Care 6:279-283, 2011

Denkert C, Sinn BV, Issa Y, Maria Müller B, Maisch A, Untch M, von Minckwitz G, Loibl S: Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts. Breast Care (Basel) 6(4):265-272, 2011

Loibl S, Doering G, Müller L, Grote-Metke A, Müller R, Tomé O, Wiest W, Maisch A, Nekljudova V, von Minckwitz G: Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial. Breast Care 6:457-461, 2011

Alvarez RH, Guarneri V, Icli F, Johnston S, Khayat D, Loibl S, Martin M, Zielinski C, Conte P, Hortobagyi GN: Bevacizumab Treatment for Advanced Breast Cancer. Oncologist. 2011 Oct 5. [Epub ahead of print]

Loibl S, Müller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B, Kulmer U, Alles JU, Mehta K, Denkert C: Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 130(2):477-87, 2011

von Minckwitz G, Loibl S, Jackisch C, Paepke S, Nestle-Kraemling C, Lux MP, Maass N, Schmutzler R, du Bois A, Wallwiener D, Vescia S, Budischewski K, Kaufmann M: The GISS Trial: a Phase II Prevention Trial of Screening Plus Goserelin, Ibandronate, versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. Cancer Epidemiol Biomarkers Prev. 20(10):2141-9, 2011

Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S: Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 29(25):3351-7, 2011

von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S; On behalf of the GBG 26/BIG 03-05 study group and participating investigators: Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 47(15):2273-2281, 2011

Baumann K, Pfisterer J, Wimberger P, Burchardi N, Kurzeder C, du Bois A, Loibl S, Sehouli J, Huober J, Schmalfeldt B, Vergote I, Lück HJ, Wagner U: Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group. Gynecol Oncol. 123(1):27-32, 2011

Denkert C, Darb-Esfahani S, Loibl S, Anagnostopoulos I, Jöhrens K: Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. Semin Immunopathol. 33(4):341-51, 2011

von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C, Holms F, Eidtmann H, Dietrich K, Just M, Clemens MR, Hanusch C, Schrader I, Henschen S, Hoffmann G, Tiemann K, Diebold K, Untch M, Denkert C: Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat. 2011 Jun 12. [Epub ahead of print]

Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer H, Conrad B, Ortmann O, Fehm T, Rezai M, Mehta K, Loibl S on behalf of the German Breast Group Investigators: Effect of LHRH agonists on ovarian function after modern-type adjuvant breast cancer chemotherapy : The GBG 37 "ZORO" study. J Clin Oncol. 29(17):2334-41, 2011

von Minckwitz G, Müller M.B, Loibl S, Budczies J Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, du Bois A, Zahm DM, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, Denkert C for GBG investigators: Cytoplasmic Poly(Adenosine Diphosphate-Ribose) Polymerase Expression Is Predictive and Prognostic in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy. J Clin Oncol. 29(16):2150-7, 2011

Loibl S, Skacel T, Nekljudova V, Lück HJ, Schwenkglenks M, Brodowicz T, Zielinski C, von Minckwitz G: Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer– a pooled analysis. BMC Cancer. 12;11:131, 2011

Hilvo M, Denkert C, Lehtinen L, Muller B, Brockmoller S, Seppanen-Laakso T, Budczies J, Bucher E, Yetukuri L, Castillo S, Berg E, Nygren H, Sysi-Aho M, Griffin JL, Fiehn O, Loibl S, Richter-Ehrenstein C, Radke C, Hyotylainen T, Kallioniemi O, Iljin K, Oresic M: Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res. 71(9):3236-3245, 2011

Untch M, Fasching P.A, Konecny G, von Koch F, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Schuster T, Nekljudova V, Loibl S, von Minckwitz G on behalf of the AGO PREPARE investigators: PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard dosed epirubicin / cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer – results at the time of surgery. Ann Oncol. 22(9):1988-98, 2011

Untch M, von Minckwitz G, Konecny G, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Beckmann M.W, Salat C, Harbeck N, Müller M, Schmidt M, Hasmüller S, Lenhard M, Nekljudova V, Loibl S, Fasching P.A, on behalf of the AGO PREPARE investigators: PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose intensified chemotherapy with epirubicin, paclitaxel and CMF versus standard dose and schedule of epirubicin / cyclophosphamide followed by paclitaxel without CMF ± darbepoetin alfa in primary breast cancer – outcome on prognosis. Ann Oncol. 22(9):1999-2006, 2011

Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Müller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, Hoffmann G, Heinrich G, Grasshoff ST, Ulmer HU, Denkert C, von Minckwitz G: Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res Treat. 126(1):109-17, 2011

Loibl S, Lintermans A, Dieudonné AS, Neven P: Management of menopausal symptoms in breast cancer patients. Maturitas. 68(2):148-54, 2011

von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Mehta K, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jüni P: Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 125(1):145-56, 2011

Loibl S, Mueller V, von Minckwitz G, Conrad B, Koehne CH, Kremers S, Forstbauer H, Linder M, Nekljudova V, Moebus V; On behalf of the GBG/AGO/NOGGO study groups: Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer. 19(11):1789-95, 2011

Mitglieder der German Breast Group präsentierten im Jahr 2011 folgende Beiträge auf internationalen Kongressen:

SABCS

de Boer R, Bundred N, Eidtmann H, Neven P, von Minckwitz G, Martin N, Modi A, Coleman R: Long-Term Survival Outcomes among Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow-Up of ZO-FAST. Cancer Res 71(24 Suppl.): 96s, 2011
Möbus V, Diel IJ, Elling D, Harbeck N, Jackisch C, Thomssen C, Untch M, Conrad B, Schneeweiss A, Kreienberg R, Huober J, Müller V, Lück HJ, Bauerfeind I, Loibl S, Nekljudova V, von Minckwitz G for the GBG/AGO study groups: Gain study: A phase III trial to compare ETC vs. EC-TX and Ibandronate vs. observation in patients with node-positive primary breast cancer – 1st interim EFFICACY analysis. Cancer Res 71(24 Suppl.): 100s, 2011

von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Kümmel S, Paepke S, Schneeweiss A, Untch M, Michael Zahm D, Mehta K, Loibl S: Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients – Results of the GeparTrio trial. Cancer Res 71(24 Suppl.): 103s, 2011

Huober J, Hanusch C, Fasching P, Rezai M, Eidtmann H, Kittel K, Schwedler K, Tesch H, Höß C, Mau C, Khandan F, Krabisch P, Loibl S, Nekljudova V, Untch M von Minckwitz G for the GBG and AGO-B study groups: Neoadjuvant CHEMOTHERAPY of Paclitaxel with or Without Rad001 Results of the NON-Responder Part of The GEPARQUINTO study (GBG 44). Cancer Res 71(24 Suppl.): 105s, 2011

Loibl S, von Minckwitz G, Blohmer JU,Costa SD, Eidtmann H, Fasching P, Gerber B, Hilfrich J, HuoberJ , Jackisch C, Kaufmann M, Konecny G, Denkert C, Nekljudova V, Mehta K, Untch M for the GBG and AGO-B study groups: pCR as surrogate in HER2-positive patients treated with trastuzumab - taking into account anti-HER2 treatment. Cancer Res 71(24 Suppl.): 111s, 2011

von Minckwitz G, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Mehta K, Loibl S, Untch M for the GBG and AGO-B study groups: Local recurrence risk after neoadjuvant chemotherapy. Pooled analysis on 5477 breast cancer patients. Cancer Res 71(24 Suppl.): 142s, 2011

Brase JC, Gehrmann MC, Petry C, Weber KE, Schmidt M, Kölbl H, Brauch H, Schwab M, Müller V, Jänicke F, Rody A, Kaufmann M, Filipits M, Gnant M, Denkert C, Loibl S, von Minckwitz G, Kronenwett R: The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer. Cancer Res 71(24 Suppl.): 187s, 2011

Eidtmann H, Kittel K, Rezai M, Tesch H, Ulmer HU, Stirnberg S, Belau A, Mau C, Stickeler E, Schrader I, Fasching P, Salat C, Abdallah A, Holms F, Schwedler K, Nekljudova V, Loibl L, von Minckwitz G: Surgical complications from the GeparQuinto trial of patients receiving preoperative Bevacizumab. Cancer Res 71(24 Suppl.): 237s, 2011

Coleman R, De Boer R, Eidtmann H, Neven P, von Minckwitz G, Martin N, Modi A, Bundred N: Influence of Delayed Zoledronic Acid Initiation on Disease-Free Survival in Postmenopausal Women with Endocrine Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole: Exploratory Analyses from the ZO-FAST Trial. Cancer Res 71(24 Suppl.): 325s, 2011

Witzel ID, Loibl S, von Minckwitz G, Abdallah A, Kühn T, Overkamp F, Fehm T, Schrader I, Uleer C, Kohls A, Stirnberg S, zu Eulenburg C, Untch M, Müller V: Predictive Value of HER2 Serum Levels in Patients Treated with Lapatinib or Trastuzumab – A Translational Project in the Neoadjuvant "Geparquinto" Trial. Cancer Res 71(24 Suppl.): 454s, 2011

von Minckwitz G, Baselga J, Bradbury I, de Azambuja E, Scullion MJ, Ross G, Saini KS, Piccart-Gebhart M: Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of Breast Cancer: APHINITY (BIG 4-11/BO25126/TOC4939g). Cancer Res 71(24 Suppl.): 602s, 2011

von Minckwitz G, Cortés J, Gligorov J, Marschner NW, Puglisi F, Vrdoljak E, Duenne A-A, Zielinski C: TANIA: A Randomized Phase III Trial Evaluating Continued and Reintroduced Bevacizumab (BEV) in Patients Previously Treated with 1st-Line BEV for Locally Recurrent/Metastatic Breast Cancer (LR/mBC). Cancer Res 71(24 Suppl.): 621s, 2011

de la Haba HR, von Minckwitz G, Martín M, Morales S, Crespo C, Guerrero A, Antón A, Gil M, Muñoz M, Carrasco E, Rodríguez C, Porras I, Aktas B, Schoenegg W, Tio J, Mehta K, Loibl S, on behalf of GEICAM and GBG: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the LEA study. Cancer Res 71(24 Suppl.): 625s, 2011

ASCO Breast

von Minckwitz G, Darb-Esfahani S, Loibl S, Tesch H, Huober J, Solbach C, Holms F, Eidtmann H, Diedrich K, Just M, Clemens M, Hanusch C, Schrader I, Henschen S, Hoffmann G, Tiemann K, Diebold K, Untch M, Denkert C: Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer: Results from the GeparQuattro study (GBG 40). ASCO Breast 2011 (Poster)

Senologie

Maisch A, Guo X, Loibl S, Untch M, Möbus V, Schwedler K, Fasching P.A, Barinoff J, Holms F, Thomssen C, Zahm D.M, Kreienberg R, Hauschild M, Eidtmann H, Tauchert S, Mehta K, von Minckwitz G: Wiedereinsatz von Taxanen beim rezidivierten Brustkrebs von Patientinnen, die mit einer (neo-) adjuvanten Taxan-haltigen Chemotherapie behandelt wurden. Senologie 2011 (Poster)

ASCO

Loibl S, Bruey J, von Minckwitz G, Huober J, Press M.F, Darb-Esfahani S, Solbach C, Denkert C, Tesch H, Holms F, Fehm T, Mehta K, Untch M: Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study. J Clin Oncol 29: 2011 (suppl; abstr 530)

von Minckwitz G, Kaufmann M, Kuemmel S, Fasching P. A, Eiermann W, Blohmer J.U, Costa S.D, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J. B, Hanusch C. A, Konecny G. E, Fett W, Stickeler E, Harbeck N, Mehta K, Loibl S, Untch M, GBG and AGO-B study groups: Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. J Clin Oncol 29: 2011 (suppl; abstr 1028)

Guo X, Loibl S, Untch M, Möbus V, Schwedler K, Fasching P. A, Barinoff J, Holms F, Thomssen C, Zahm D. M, Kreienberg R, Hauschild M, Eidtmann H, Tauchert S, Mehta K, von Minckwitz G, German breast group and AGO-B Study Group: Rechallenging taxanes in recurrent breast cancer in patients treated with (neo-) adjuvant taxane-based therapy. J Clin Oncol 29: 2011 (suppl; abstr 1055)

Conrad B, Harbeck N, von Minckwitz G, Wuellner M, Warm M, Schwedler K, Gerber B, Schrader I, Eidtmann H, Mehta K, Loibl S, GBG/AGO-B study groups: SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in women with primary breast cancer (BC; GBG 45). J Clin Oncol 29: 2011 (suppl; abstr 1059)

Gerber B, Eidtmann H, Rezai M, Fasching P. A, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C. A, Kreienberg R, Solbach C, Jackisch C, Kunz G, Blohmer J.U, Huober J.B, Hauschild M, Loibl S, Nekljudova V, Untch M, von Minckwitz G, GBG/AGO study groups: Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44). J Clin Oncol 29: 2011 (suppl; abstr 1006)

Wenners A. S, Mehta K, Loibl S, Park H, Arnold N, Hamann S, Weimer J, Ataseven B, Schem C, Khandan F, Thomssen C, Jonat W, Holzhausen H, von Minckwitz G, Denkert C, Bauer M: Evaluation of neutrophil gelatinase-associated lipocalin (NGAL) as predictor of response to neoadjuvant chemotherapy (NACT) in primary breast cancer. J Clin Oncol 29: 2011 (suppl; abstr 595)

Ruckhäberle E, Karn T, Denkert C, Loibl S, Ataseven B, Reimer T, Hanker L. C, Sänger N, Holtrich U, Kaufmann M, Darb-Esfahani S, Nekljudova V, von Minckwitz G: Predictive value of sphingosine kinase-1 expression in neoadjuvant treatment of breast cancer. J Clin Oncol 29: 2011 (suppl; abstr 615)

Heitz F, Sinn B, Loibl S, du Bois A, Jackisch C, Kuemmel S, Denkert C, Barinoff J, Mehta K, von Minckwitz G, on behalf the GeparTrio trialists: Effect of estrogen receptor beta expression (ERße) in triple-negative breast cancer (TNBC) patients treated in the neoadjuvant GeparTrio trial. J Clin Oncol 29: 2011 (suppl; abstr 1069)

Budczies J, Denkert C, Mueller B, Brockmoeller S.F, Dietel M, Radke C, Loibl S, von Minckwitz G, Griffin J.L, Oresic M, Wohlgemut G, Fiehn O: Separation of breast cancer from normal tissues using GC-MS-based metabolite profiling. J Clin Oncol 29: 2011 (suppl; abstr 10514)

Denkert C, Kronenwett R, Loibl S, Nekljudova N, Darb-Esfahani S, Gerber B, Sinn B, Petry C, Bauerfeind I, Budczies J, Rezai M, Dietel M, Schrader I, Kunz G, von Minckwitz G, GBG and AGO-B study groups: RNA-based molecular tumor typing and immunological infiltrate as response predictors to neoadjuvant chemotherapy: Prospective validation in the GeparQuinto-PREDICT substudy. J Clin Oncol 29: 2011 (suppl; abstr 10526)

Filtern Sie den Publikationsbereich unserer Webseite
540 Publikationen
Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer.
Patient-reported outcomes (PROs) for the intergroup sentinel mamma study (INSEMA, GBG75, ABCSG43): Persistent impact of axillary surgery on arm and breast symptoms in early breast cancer.
Phase III postneoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA.
Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple‑negative breast cancer (mTNBC).
Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05).
Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer.
Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05).
Immunological markers in patients with breast cancer occurring during pregnancy - Results from GBG BCP study.
Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study.
Randomized comparison of adjuvant aromatase inhibitor exemestane + ovarian function suppression (OFS) vs tamoxifen + OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer: update of the TEXT and SOFT trials.
Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial.
Impact of body mass (BMI) and weight change after adjuvant treatment in patients (pts) with HER2-positive early breast cancer.
Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up.
Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).
Health economic properties of Palbociclib in breast cancer patients with high risk of relapse following neoadjuvant therapy – results from the Penelope-B trial.
Phase III postneoadjuvant study evaluating Sacituzumab Govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA
A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE).
Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib.
PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer.
Trastuzumab-Deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer (BC) after neoadjuvant therapy (NAT): a randomized, phase 3 trial (DESTINY-Breast05).
Characteristics of patients with brain metastases from HER2-positive breast cancer. oral presentation.
Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial.
OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.
Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.
Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.
Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.
BACH1 and HIF1α predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC).
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.
Baseline menopausal status, Ki-67 and stromal tumor-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): exploratory analysis in GeparSixto.
Characteristics of patients with brain metastases from HER2-positive breast cancer.
Impact of body mass index (BMI) on prognostic and predictive value of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): a pooled analysis of six neoadjuvant trials.
Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
Early intervention for and management of alpelisib (ALP)-induced hyperglycemia: case studies from the Phase III SOLAR-1 trial.
Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients (pts) with metastatic triple-negative breast cancer (mTNBC).
post-neoadjuvant
Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: a randomized, phase 3 trial (DESTINY-Breast05).
6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: a STEPP analysis of the APHINITY (BIG 4-11) trial.
CelTIL score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial.
Clinical Outcomes of Alpelisib Plus Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer With PIK3CA Alterations Detected in Plasma ctDNA by Next-Generation Sequencing: Biomarker Analysis
Timelines to initiate an adjuvant phase III trial across the globe: a sub-analysis of the APHINITY trial.
Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B.
12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ.
Treatment exposure and discontinuation in the PALLAS trial: PALbociclib CoLlaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for HR+/HER2- early breast cancer.
Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry – comparison of three different prognostic scores. oral presentation.
Predictors of efficacy in patients (pts) with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Subgroup analyses of PALOMA-3.
Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases.
Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial.
Prognostic Factors for Overall Survival in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Analyses From PALOMA-3.
A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze).
Overall Survival (OS) Results From SOLAR-1, a Phase 3 Study of Alpelisib (ALP) + Fulvestrant (FUL) for Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Advanced Breast Cancer (ABC).
Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332).
urvival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts)
Characterization of gene fusions in paired primary and metastatic samples of breast cancer in the AURORA molecular screening program.
Influence of denosumab on disseminated tumor cells (DTC) in the bone marrow of breast cancer (BC) patients with neoadjuvant treatment: A GeparX translational substudy.
Factors associated with axillary conversion after neoadjuvant chemotherapy in initially node positive breast cancer patients: A transSENTINA analysis.
GAIN-2: Neo-/adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS).
Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial.
Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.
Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different prognostic scores.
Tumour mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
Patients (pts) preference for different administration methods of trastuzumab (T) in pts with HER2+ early breast cancer (BC) treated within the GAIN-2 trial.
Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE.
Cancer Management and Outcome of young patients (pts) with breast cancer (BC) diagnosed at 40 years (yrs) or younger.
Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with Atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of Atezolizumab/Placebo (GeparDouze).
Germline (g)BRCA1/2 mutations (m) and hematological toxicities in patients (pts) with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT).
Germline mutation status and therapy response in high-risk early-stage breast cancer: A secondary analysis of the GeparOcto randomized clinical trial (NCT02125344).
Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study.
Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC).
Caveolin gene expression predicts for response and clinical outcomes of patients treated with preoperative paclitaxel-based chemotherapy regimens in early stage breast cancer.
Sole (study of letrozole extension), a phase 3 randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women
Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis.
neoadjuvant
A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze.
Germline (g)BRCA1/2 mutations (m) and hematological toxicities in patients (pts) with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT).
Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy
(IBIS-II investigators). Ten year results of the international breast cancer intervention study II.
Histological and epigenetic analyses of placenta tissue from breast cancer patients and healthy participants.
Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC).
Landscape of immune-cell signatures in early high-risk breast cancer (BC) reveals clinically-relevant enrichment of immune subpopulations.
Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer - First results of the GeparX study.
Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - an analysis of the GeparSepto trial.
Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients.
Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: an update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine
Utility of the CPS+EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials.
Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study.
Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC).
Clinical relevance of collagen protein degradation markers C3M and C4M in the serum of breast cancer patients treated with neoadjuvant therapy in the GeparQuinto trial.
Update NSEMA-Studie. DGS 2019; oral presentation.
Expression von PD-L1 und dynamische Veränderungen tumor-infiltrierender Lymphozyten bei neoadjuvanter Chemotherapie mit Immun-Checkpunkt-Blockade beim frühen triple-negativen Mammakarzinom. DGP 2019, AG05.02, oral presentation.
Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial.
Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.
NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts)
Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.
Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.
Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab
Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344).
GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts)
Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.
Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: pooled analysis based on the GBG database.
Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: pooled analysis of 484 patients from three prospective multicentre GBG trials.
GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.
Para-necrotic expression of VEGFA metagene signature identified by single-cell profiling.
(on behalf of the GBG neoadjuvant and translational subboard). Expression of ER, PR, HER2 and Ki-67 in the neoadjuvant GeparX trial - comparison of central immunohistochemistry (IHC) with an automated cartridge-based system for mRNA assessment.
Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab
mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)- Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial.
Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial.
Cancer management and outcome of very young non-pregnant patients with breast cancer diagnosed at 40 years or younger.
Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy – Results of a pooled analysis based on the GBG meta-database.
Similarities between low hormone receptor positive and hormone receptor negative breast cancer: An analysis of 4366 patients from multicenter clinical trials.
Single-cell profiling identifies hypoxic carcinoma cells as source of an immunosuppressive VEGFA metagene.
Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy with durvalumab - Results from the prospectively randomized GeparNuevo trial.
Biomarker analysis of CDK 4/6 and endocrine pathways in hormone-receptor positive (HR+) advanced breast cancer (ABC) bone only disease patients: A joint analysis of PALOMA-2 and PALOMA-3 studies.
A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)
A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze.
ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer.
Longitudinal ctDNA sequencing using an expanded genomic panel in the PALOMA3 trial of palbociclib plus fulvestrant.
A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy.
Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients
Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue or an aromatase inhibitor + GnRHa in male breast cancer patients
Validation of the MammaTyper® pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC).
Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes.
Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study.
PATINA: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy (ET) vs. Anti-HER2 Therapy + ET after Induction Treatment for Hormone Receptor Positive (HR+)
Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97.
Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3.
Physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey.
Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial.
Application of CDK4/6 inhibitors in practice: Effect of online education on clinician competence and confidence.
Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial).
palliativ
A randomized, open-label, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment in patients with hormone receptor-positive, HER2-negative metastatic breast cancer (PADMA);
Anti-hormonal maintenance treatment with/without the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in HR+/HER2- metastatic breast cancer: a phase II trial (AMICA) GBG 97
Investigating Denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX)
A randomized, double-blind, phase III trial of neoadjuvant chemotherapy with Atezolizumab/Placebo in patients with triple-negative breast cancer followed by adjuvant continuation of Atezolizumab/Placebo (GeparDouze); poster
Changes in hormone levels (E2, FSH, AMH) and fertility of young women treated with neo-/adjuvant chemotherapy (CT) for early breast cancer (EBC)
Tumor infiltrating lymphocytes predict better DFS from intense dose-dense (idd) EPC regimen - results from the German Adjuvant Intergroup Node-positive Study (GAIN-1); oral presentation
Erste Daten der MALE Studie: Welche Hormontherapie ist die effektivste beim Mann?; oral presentation
Update INSEMA-Studie
Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).
Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients
Investigating denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules: 2x2 factorial design (GeparX)—An interim safety analysis.
NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.
Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.
Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study.
Tumor infiltrating lymphocytes to predict DFS from intense dose-dense (idd) EPC regimen: Results from the German Adjuvant Intergroup Node-positive study (GAIN-1).
Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the “SOLE” trial.
Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer: A genome-based investigation in the neoadjuvant GeparSepto trial
Association of clinical/pathological parameters with axillary involvement in early breast cancer in patients with limited sentinel node involvement after neoadjuvant chemotherapy (NACT).
Mutational diversity and therapy response in breast cancer - a sequencing analysis in the neoadjuvant GeparSepto trial.
Lessons from the neoadjuvant setting on how best to choose adjuvant therapies. Breast 2011
Author reply. Cancer 2006